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Bacterial infection is considered as one of the major threats to human life as well as to the global 
economy; especially with the increasing number of new multidrug resistant strains. Timely as 
well as accurate diagnosis of these infections significantly affect the treatment strategies and the 
prognosis of the disease. Until now, isolation and culturing of the organism is considered to be 
the gold standard for bacterial infection diagnosis. Conversely, this method is time consuming 
and labor-intensive. However, with the exponential development in the area of 
radiopharmaceutics, new imaging probes for the diagnosis of bacterial infection are emerging. 
The aim of this study focuses particularly on the development of potential radiotracers for 
imaging of bacterial infection. 
In this thesis, several topics related to bacterial infection imaging were explored. These topics 
can be categorized into sections namely; a review on the synthetic approaches of existing 
potential probes for bacterial imaging, novel on and off resin synthesis of a bifunctional chelator 
NODASA with a model peptide and lastly, an efficient method for the synthesis of LL37 and 
NODAGA-LL37 along with its evaluation for bacterial specificity. 
The first concern about radio tracers is the requirement for an ideal radiopharmaceutical for direct 
imaging of bacteria. The prime aim of the first part of this thesis is to evaluate the current 
approaches used for the synthesis of radiolabelled probes for bacterial infection identification as 
it is clear that such a review will be timeous. In this regard, a review of published work was 
carried out on the clinical as well as preclinical available probes. Furthermore, existing 
radiolabelling procedures and suggested mechanisms of radio tracer uptake is also discussed. 
These molecular probes comprises of leukocytes, antibodies, small molecules, peptides, 
antibiotics, macrolides, vitamins, oligomers and siderophores. 
Bifunctional chelators (BFCs) are one of the key elements of a successful radiotracer, which act 
as a linker between the tracer moiety and the radio isotope. One of the major aims of this study 
is to develop a method for the synthesis of bifunctional metal chelator NODASA, a potential 
chelator for radiolabelling.  Herein, a facile economic on and off resin method for the synthesis 
of potential bifunctional chelator “NODASA” functionalized peptide is presented. The seven step 
synthesis was initiated with a Michael addition reaction between monomethyl fumarate and 
1,4,7-triazacyclononane.  The final product of NODASA functionalized peptide was obtained 
with an isolated yield of 84%. 
A potential human antimicrobial peptide LL37 possesses impending therapeutic values due to its 




goals of this study. In this regard, a highly efficient and optimized methodology for the synthesis 
of LL37 on solid phase using microwave energy was developed. During this method development 
it was concluded that uronium coupling reagents along with standard conditions were inadequate 
for the synthesis of 20th amino acid residue onwards. Val and Ile amino acid coupling was 
revealed as the key problematic reaction in the segmentation approach of synthesizing the 
peptide. It was also found that DIC/OxymaPure in THF is a better combination of reagents for 
this coupling. The synthesized peptide was further verified for its antimicrobial activity.   
In the last part of this study the aim was to explore the radiolabelling potential of LL37 and its 
usability as a radiotracer. For this purpose LL37 was functionalized with bifunctional chelator 
NODAGA. NODASA-LL37 was also labelled with cold/hot gallium successfully. This complex 
was further evaluated in vitro for its bacterial selectivity over mammalian cell line.  
With the rapid development of bacterial resistance and the development of “super bugs” there is 
an urgent need for diagnostic tools which can provide a faster and efficient detection of 
pathogenic microorganisms. Radiopharmaceutics is an ideal candidate to solve this problem, 
especially due to its high selectivity, sensitivity and non-invasive nature. In this thesis, an effort 
was put forward to answer the critical questions regarding the development of synthetic methods, 
purification and characterization of the antimicrobial peptide LL37. Firstly, a combination of 
different coupling reagents were used for the optimization of the synthesis, from this study we 
were able to conclude that the DIC/OxymaPure is better than the HBTU/DIPEA and 
HATU/DIPEA systems. This method can now be utilized for the large scale production of LL37. 
In addition to this, a facile seven step method for the synthesis of the bifunctional chelator 
NODASA functionalized peptide was developed. In this study a NODASA functionalized 
peptide was conjugated with cold gallium which, demonstrating it as a potential PET agent for 
molecular imaging. This route offers a simple and inexpensive alternative to commercially 
available NODASA and can be coupled with various other peptides. Finally, LL37 was also 
functionalized with the chelator, NODAGA, and subsequently labelled with natGa. This complex 
showed significant affinity towards bacterial cells in comparison with mammalian cells and 
providing evidence that NODAGA-LL37 could be a potential radiotracer for bacterial infection 
imaging.   
Abbreviations: NODAGA: 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid; NODASA: 
1,4,7-Triazacyclononane-1-succinic acid-4,7-diacetic acid 
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Biological processes can be visualized, characterized and measured in vivo with the aid of 
molecular imaging [1].  This exponentially growing technique is utilized to monitor molecules 
or cellular processes for the diagnosis and/or management of diseases and disorders.  Some of 
these imaging procedures include positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT) that acquire images by detecting signals from 
radiolabelled tracers that have to be injected into the test subjects.  However, endogenous 
molecules or exogenous molecular probes are generally considered in some modalities like 
optical imaging and magnetic resonance imaging (MRI) to monitor disease progression.  Due to 
its critical role in medical diagnostics, the design and development of radiotracers are becoming 
a focal area in molecular imaging research [2].  Characteristically, a radiotracer is equipped with 
a targeting moiety, a signaling radioisotope and a linker connecting these components.  
2. Bifunctional chelators in radiopharmaceutics.   
Radio-metals carry promise as a tool towards the diagnosis, as well as for monitoring the 
progression of many diseases.  These isotopes have to be impounded by metal chelators in order 
for use in a biological system.  Based on the compatibility, these organic compounds are able to 
make stable complexation products with a particular radio-metal.  An ideal chelator binds to the 
radio-metal well enough so that it can be delivered to the desired site without trans-chelation 
thereby improving therapy or in vivo diagnosis [3].  In radiopharmaceutics, typically utilised 
ligands for metal binding are mostly bifunctional chelators (BFCs).  These are distinctive 
chelators with a functional group to form a covalent bond with the tracer molecules, such as, but 
not limited to antibodies, nucleotides and peptides.  Such functional groups can be carboxylic 
acids/activated esters, isothiocyanates or maleimides for amide, thiourea and thiol coupling 
agents, respectively [4, 5].  Moreover, click chemistry based reactions which are either copper-
free (Diels-Alder and strain-promoted azide-alkyne cycloadditions click reactions) or copper 
catalyzed (azide-alkyne Huisgen 1,3-dipolar cycloaddition “click” reactions) are also gaining 
popularity in bio-conjugate chemistry [6].  Chelators play a major role in the pharmacokinetics 
of the radiochemical; it has been noted that by only changing the ligand the biodistribution of 
peptide-conjugates are affected [7].  A simple synthetic strategy which avoids diastereospecific/ 
non-enantio and stereoisomer reactions are always desirable for BFC synthesis.  In addition, it 




tracers/moieties to impact biodistribution by altering charge and polarity [3].  Broadly, BFCs are 
categorized into macrocyclic and acyclic chelators.  However, macrocyclic chelators have an 
advantage over its counterpart acyclic ligands as it inherits a pre-organized binding pocket for 
metal ions which minimizes the entropic loss during radio-isotope coordination.  Conversely, 
acyclic chelators change their physical orientation and geometry drastically for the positioning 
of the donor atoms to form the conjugate product with the metal ion.  This phenomenon leads to 
a substantial drop in entropy as compared to macrocyclic chelators [8].  A few popular 
macrocyclic chelators are 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 
1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), diamsar, 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA), 1,4,7,10,13,16-hexaaza-cyclohexadecane 
Nʹ,Nʹʹ,Nʹʹʹ, Nʹʹʹʹ,Nʹʹʹʹʹ,Nʹʹʹʹʹʹ-hexaacetic acid (HEHA), 1,4,7,10,13-pentaazacyclopentadecane- 
Nʹ,Nʹʹ,Nʹʹʹ, Nʹʹʹʹ,Nʹʹʹʹʹ-pentaacetic acid (PEPA) (Figure 1) and their derivatives; on the other hand 
diethylenetriaminepentaacetic acid (DTPA), N,N0-bis(2-hydroxybenzyl)-ethylenediamine-N,N-
diacetic acid (HBED), N,N-(methylenephosphonate)-N,N0-[6-(methoxycarbonyl)pyridin-2-yl]-
methyl-1,2-diaminoethane (H6phospa), bipyridine-chelator  (BPCA), desferrioxamine B (DFO) 
and CP256 (Figure 2) are some examples of widely studied acyclic BFCs [3].  Alongside the 
chelating moiety, there are a variety of options to choose with regards to the radio-nucleoid which 
includes  18F, 67/68Ga, 99mTc, 111In, 177Lu, 64Cu, 44Sc, 86Y and 89Zr [3].  These ligands have been 
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Figure 2. Acyclic chelators commonly used for radioisotope conjugation 
3. Radio imaging a need for bacterial infection 
Bacterial infection is a major threat to human health; and is still recognized as one of the most 
vicious causes of mortality and morbidity worldwide [9].  Because of its heterogeneous nature, 
infectious diseases are associated with a variety of different clinical signs and symptoms.  They 
may be systemic or localized in one foci and often reoccurs; in many cases these infections 
require long term treatment [10].  Therefore, in a clinical set up it is difficult to distinguish 
between infection and aseptic inflammation in addition to its size and distribution throughout the 
body.  This in turn affects the treatment strategies that are employed [11].  In general, the 
diagnosis of infectious diseases is carried out by using clinical history, physical inspection, 
pathogen identification in suspected sample and by imaging approaches.  Though the application 
of imaging techniques has advantages due to its non-invasive nature, but there is a significant 
difference between the uses of non-radionuclide medicine and radionuclide imaging.  Imaging 
techniques such as ultrasound, plain radiography and computed tomography are based on 
anatomical changes, which arise in the advanced stages of infectious diseases [12].  This 
highlights the need to develop radio nuclear approaches for the early and precise identification 
of infectious lesions.  Due to the knowledge gained and better understanding, we now have in 




imaging bacterial infections [13-15].  This development in radiopharmaceutics is feeding the 
clinician with invaluable information regarding the infection, thereby giving an opportunity to 
commence with the best therapeutic strategies for the patients.  Up till now, various molecules 
have been taken into consideration as radio-labelled tracers to detect infection foci; this includes 
leukocytes, antibiotics, antibodies, peptides, siderophores, bacteriophages, vitamins, 
carbohydrates and aptamers [16-19].  However, very few from this have been clinically approved 
for human use; that taken into account includes 111In-oxine-Leukocyte-SPECT, 99mTc-HMPAO-
Leukocyte-SPECT, 99mTc-Sn-Colloid “LLK”-SPECT, 99mTc-Besilesomab-SPECT, 99mTc-
Sulesomab-SPECT, 18F-FDG-PET and 67Ga-citrate-SPECT [20-24].  
4. Peptides as radiotracers 
Recently, attention has been drawn to antimicrobial peptides (AMPs) for use as a guiding 
molecule for the radio-isotope and in PET tracer development [25].  Evolutionarily, AMPs are 
the ancient ordinance of the immune system.  They are widely spread amongst the animal species, 
as well as in the plant kingdom; this suggests the involvement of AMPs in the evolution of 
multicellular organisms.  These peptides are still an effective and integral part of the primary host 
defense system regardless of its ancient lineage [26].  They are of greater interest because of the 
fact that peptides show low toxicity and immunogenicity with high specificity and binding 
capability towards its desired target [27, 28].  The mechanism of action of AMPs are based on 
differences in the basic design of the cellular membrane of multicellular organisms and microbes.  
The outermost bilayer of bacteria is composed of heavily condensed negatively charged lipids, 
whereas the outer layer of the animal and plant cells are populated mainly with neutral lipids 
[29].  This feature gives the AMPs specificity towards bacterial cells and accumulation at the 
infectious site; making them promising PET and SPECT tracers, for imaging bacterial infections 
[30].  Even though the use of AMPs in radiopharmaceutics is not a new concept [31, 32]; only a 
few members of this group have been evaluated so far [33].  Some of the AMPs studied so far 
include ubiquicidin, human neutrophil peptide, neutrophil elastase inhibitor peptide, human-β-
defensin and human lactoferrin-derived peptide.  In addition to the aforementioned peptides, 
human cathelecidin antimicrobial peptide LL37 is also extensively involved with the innate 
immune system and can be useful in radiopharmaceutics.  This antimicrobial peptide is found in 
various cell lines (human squamous epithelia, granulocytes and neutrophil) and other bodily 
fluids [34].  LL37 is involved in neutralizing biologically active molecules, which are present in 
the bacterial cell wall and also acts as growth inhibitor [35, 36].  Moreover, this antimicrobial 
peptide also contributes towards chemotaxis, cell migration, cytokine production, angiogenesis 
and histamine release [34]. Due to its association with the human defense system; it can be 




5. LC-MS as a means for peptide/protein quantification 
In the current era, peptide and protein quantification is quickly gaining momentum due to the 
increasing demand for them to be evaluated as diagnostic and therapeutic molecule.  Moreover, 
there is a shift in the trend of drug discovery towards a target oriented approach and therefore a 
need for the precise and accurate quantification of these molecules [37].  In that context, liquid 
chromatography–mass spectrometry (LC-MS) which is considered as the gold standard for small 
molecule quantification is now showing great potential towards larger molecules (such as peptide 
and protein) determination, due to its inherent advantages [38, 39].  The advantages of this 
technique over immune based assays include a shorter method development time, lack of 
antibody requirement, high specificity as well as sensitivity (up to ng/ml or pg/ml concentrations) 
and its ability to monitor product degradation.  Based on the size of the peptide/protein, LC-MS 
quantification can be broadly categorized into 1) a bottom up approach where the molecule 
(usually >10-15 kDa), is digested with an enzyme and is followed by the liquid chromatography–
mass spectrometry/mass spectrometry (LC-MS/MS) analysis; and 2) a top down approach where 
the native molecule (usually <10-15 kDa) is analyzed directly, either by liquid chromatography–
high resolution mass spectrometry (LC-HRMS) or LC-MS/MS (Figure 3).  A variety of sample 
preparation methods such as solid phase extraction, protein precipitation, immuno-capture 
enrichment and depletion of high-abundant proteins can be integrated into the LC-MS workflow 
based on the nature of the analyte and to increase sensitivity of the method [37]. 
 






6. Research Aims and Objectives  
1. What are the current approaches used for the synthesis of radiolabelled probes for bacterial 
infection identification? 
Objective: To assess the currently available radiotracers and evaluate them for imaging of 
bacterial infections and their synthetic approaches.  
2. Till date, there is no method developed for on and off resin synthesis of bifunctional metal 
chelator 1,4,7-Triazacyclononane-1-succinic acid-4,7-diacetic acid (NODASA); is it possible to 
synthesize NODASA economically using solid phase synthesis? 
Objective: To develop a facile method for the synthesis of NODASA. 
3. LL37 is a human antimicrobial peptide, can it be produced efficiently by solid phase peptide 
synthesis? 
Objective: To develop an efficient synthetic route for the production of LL37 by solid phase 
peptide synthesis. 
4. Literature reveals that antimicrobial peptides bears the potential to be used as radiotracer for 
bacterial infection imaging, can LL37 be radiolabelled and utilized for this purpose?  
Objective: To synthesize 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid-LL37 
(NODAGA-LL37), investigate its complexation with nat/68Ga and evaluate cellular uptake of 
natGa-NODAGA-LL37. 
7. Thesis outline 
A brief review on radiotracers having potential for bacterial infection imaging will be presented 
in Chapter 2.  A facile approach for the synthesis of bifunctional chelator NODASA will be 
presented in Chapter 3.  The synthesis of antimicrobial peptide LL37 will be discussed in Chapter 
4.  The synthesis and the evaluation of nat/68Ga complexed NODAGA-LL37 will be discussed in 
Chapter 5.  Finally, in chapter 6 the overview of the results is put into perspective. 
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Abstract 
This present review provides an account on the available synthetic strategies employed to 
radiolabel commercial and potential bacteria-selective probes for tomographic imaging.  These 
molecular probes encompass leukocytes, antibodies, small molecules, peptides, antibiotics, 
macrolides, vitamins, oligomers and siderophores.  Although this technique has shown to be a 
valuable tool for non-invasive infection imaging, more development is required to create easy-
to-radiolabel kit solutions/procedures for the preparation of the probes.  
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Throughout the world, bacterial infections remain a major cause for human morbidity and 
mortality [1].  Infectious diseases are one of the oldest challengers for humans; and can be ranked 
with war and famine [2].  In this current era, the growing incident of infection and the 
development of drug resistance have a huge impact on the global economy and human health [2].  
Early detection of bacterial infection is crucial for the prognosis of the disease but insignificant 
progress has been done in this field.  Conventional ways for bacterial diagnosis are based on 
either or combination of biochemical, physical and bacterial cultures where the bacterial 
culturing can be considered as the gold standard method [3].  However, bacterial culture methods 
do not provide in vivo localization of the infection or reservoirs.  With the advancement of 
modern day technology, various diagnostic tools bear the potential for locating the site of 
infection.  Radiological techniques such as computed tomography (CT) can be advantageous for 
imaging bacterial infections but it is only useful when there is a significant anatomical change in 
potentially infected tissues.  Likewise, magnetic resonance imaging (MRI) can be applied for 
bacterial imaging aided by specific probes but it is limited to patients without claustrophobia or 
implanted medical devices.  Nuclear medicine techniques such as single photon emission 
computed tomography (SPECT) and positron emission tomography (PET) stand out as potential 
candidates because these techniques are able to locate the site of infection with the help of a 
radiolabeled biomolecule/probe [4].  Available SPECT- or PET-based probes consist of in vitro 
or in vivo (for example) radiolabeled leukocytes.  There are recurring comprehensive reports on 
the clinical use of commercially available radiotracers targeting infection and inflammation [5, 
6].  The radiolabeled probes under current studies showed the potential for targeting molecular 
components of bacteria or its metabolites resulting in specific identification of the infection site 
in contrast to the sterile inflammation [7-10].  This field of study is also positively influenced 
and expanding due to the hybridization of imaging techniques such as PET(SPECT)/CT or 
PET(SPECT)/MRI [11].  
Herein, we aim to provide a concise guide to the synthetic approaches of molecular radiotracers 
with focus on bacterial imaging aimed at medicinal chemists.  This review is divided into 
commercially available and novel probes as followed: i) clinical/preclinical availability, ii) probe 
functionalizing via suggested radiolabeling procedures and iii) probe distribution and suggested 
mechanisms of the probe uptake, internalization and signal amplification.  At the end of each 
class of radiolabeled probe, is a table summary of the transformations that provides information 
on the non-radiolabeled core, radioisotope, disease target, labeling efficiency and technique used 




2. Commercially available infection imaging probes: 
Most of the clinically used radiotracers for infection detection are based on leukocytes due to the 
fact that there is an influx of leukocytes during inflammation.  A few of these 
radiopharmaceuticals are Food and Drug Administration (FDA) approved.  These commercially 
available radiotracers can be divided broadly into i) radiolabeled leukocytes (111In-oxine-
leukocyte, 99mTc-HMPAO-leukocute and 99mTc-Stannous Colloid), ii) radiolabeled anti-
granulocyte antibodies (99mTc-Besilesomab and 99mTc-Sulesomab), iii) unspecific biomolecules 
such as 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) and 67/68Ga-citrate.  
2.1. 111In-oxine-Leukocyte 
The current “gold standard” tomographic imaging technique targeting infection is considered to 
be direct leukocyte labeling with radio metals [12].  Efficient labeling of leukocytes and its 
imaging can be obtained with 111In-oxine because of its long half-life [13].  Detection and 
localization of the infectious site is the prime area of interest for 111In-oxine-leukocyte which 
included various clinical presentations such as pulmonary infection including tuberculosis, 
endocarditis, neurological infections, fever of unknown origin, diabetic foot, inflammatory bowel 
disease, infected central venous catheters or other devices; infected joint and vascular prosthesis, 
postoperative abscesses and osteomyelitis of the appendicle skeleton [14-16].  Roca et al. 
described a method of radiolabeling necessitating at least 2 x 108 leukocytes for good labeling 
efficiencies [14].  A whole-blood sample was collected from the patient in acid-citrate-dextrose 
(ACD) anticoagulant solution containing vial, at a blood /ACD ratio of 1:5.6.  Out of that, 15 ml 
of the mixture was centrifuged at 2000 g for 10 min at room temperature to separate the blood 
cells from the cell free plasma (CFP) and the latter was used as re-suspending medium after 
labeling in the subsequent steps.  Leukocyte isolation was initiated by separating the erythrocytes 
with 10% 2-hydroxyethyl starch (HES) (molecular weight 200/0.5 or 200/0.6) by sedimentation.  
Recommended blood-ACD solution to HES ratio was 10:1 and the leukocyte-rich plasma (LRP) 
was collected with a 20G lumbar needle without disturbing the erythrocyte layer which was 
followed by centrifugation at 150 g for 5 min.  Platelet-rich plasma (PRP) was removed and the 
mixed leukocyte pellet was gently re-suspended.  An optional PBD/saline wash was advised to 
reduce the number of platelets.  For radiolabeling, 20 MBq of 111In-oxine was incubated with the 
isolated mixed leukocyte cell suspension for 10 min at room temperature with gentle periodic 
swirling.  The authors recommended working with HEPES buffer (about 6 mg/ml final 
concentration) if 111In-oxine has to be used without the buffer provided by the manufacturer.  
After incubation, at least 3 ml (up to a maximum of 10 ml) of PBS/saline was added to the 




was removed and used to calculate the labeling efficiency.  Radioactivity was measured in the 
leukocyte pellet and subsequently dissolved in 3-5 ml of previously extracted CFP [14].  
During the process of leukocyte labeling with 111In-oxine, it diffused through the lipid bilayer of 
the cell because of its neutral and lipophilic nature.  Upon internalization, the 111In-complexes 
(i.e. the radioisotope) irreversibly associate with intercellular and nucleus components and free 
oxine may experience cellular efflux. 
2.2. 99mTc-HMPAO-Leukocyte: 
Technetium-99m (99mTc) can be chelated with hexamethylpropyleneamine oxine (HMPAO) and 
has been used as a non-invasive diagnosis tool for numerous physiological abnormalities [17].  
The SPECT radioisotope 99mTc- can be chelated with HMPAO, which facilitates the uptake into 
cells [18].  Leukocyte labeling with 99mTc-HMPAO follows a similar technique to using 111In-
oxine; i.e. it needs the separation of WBC from the whole blood.  Once inside the cell, 99mTc-
HMPAO changes its lipophilic character to non-diffusible hydrophilic complexes and becomes 
trapped [19].  This compound has a half-life of 6 h and emits 140-keV γ-rays which can be 
detected by a SPECT camera [20].  The normal probe bio-distribution can be seen mainly in the 
kidney, liver and spleen with notable activity in the gastrointestinal tract and bone marrow.  
Hence, imaging of hepatic and splenic infections using 99mTc-HMPAO-Leukocyte SPECT may 
lead to suboptimal image interpretation [20].  
2.3. 99mTc-Stannous Colloid 
99mTc-labled stannous colloids (99mTc-SnC) is a radiolabeling technique to label neutrophils and 
monocytes for imaging of inflammation and spatial localization of infection for gram-positive as 
well as gram-negative bacteria [21-26].  The radiolabeling of leukocytes does not require its 
separation from the whole blood as 99mTc-SnC can selectively bind to the target immune cells in 
the infection site which make it simpler and less expensive compared to other labeling agents 
[21, 27, 28].  The 99mTc-SnC has a shelf-life of up to 6 h [29].  Colloid incubation with a 
heparinized patient whole blood sample (up to 20 mL) comprises of a 1 h syringe rotation 
followed by a brief centrifugation step to part cells and plasma supernatant prior to cell re-
suspension and re-administration into the patient.  It should be noted that 99mTc-SnC labeled 
blood cells cannot distinguish between sterile inflammation and infection [30].  It has 
unanimously been reported that its labeling efficiency is more than 95% using whole blood 
samples [27, 28, 31-33].  The detailed mechanism of action concerning 99mTc-SnC-labeling 
leukocytes may not be entirely understood [21, 22, 27, 34-36]; it is hypothesized that 
phagocytosis of the colloidal compounds and/or its reversible binding of the leukocyte to cell 





Besilesomab, a murine derived monoclonal antibody of the IgG1 κ isotype with a molecular 
weight of 150 kDa, targets the NCA-95 epitope of granulocyte or granulocyte precursors.  After 
injection of 99mTc-Besilesomab to the recipient, 10% of the compound binds to neutrophils 
whereas 20% of them freely circulate and localize in infected sites through a non-specific 
mechanism [37, 38].  99mTc-Besilesomab can be used for the diagnosis of pyrexia of unknown 
origin, appendicitis, acute myocarditis and diabetic pedal osteomyelitis but it showed variable 
results in the case of joint infection and inflammatory bowel disease [39-43].  
Radiopharmaceutical preparation of 99mTc-Besilesomab is marketed under the trade name 
Scintimun® and the kit contains Besilesomab with pre-reduced disulfide bonds. Generator-eluted 
99mTc-sodium pertechnetate is reduced by the stannous chloride (provided as a kit vial 
component) yielding 99mTc(IV), which in turn binds to the free thiol groups of the reduced 
Besilesomab [44].  The usage of Scintimun® might be challenged by: the risk of the pattern of 
human anti-mouse antibodies (HAMA) response, i.e. eliminates repeated probe administrations, 
a delayed probe accumulation at the infected site due to the high molecular weight of the 
antibody, and significant unspecific probe uptake in the liver and bone marrow [45].  99mTc-
Besilesomab-SPECT imaging is unspecific for infection. 
2.5. 99mTc-Sulesomab 
99mTc-Sulesimab is a sensitive probe primarily used to detect musculoskeletal infections.  It also 
showed to be useful in the case of diagnosing pyrexia of unknown origin as well as infection in 
soft tissues [46].  Sulesomab is a murine originated fragment antigen binding (Fab) portion of an 
IgG1 and can couple to 99mTc through its thiol groups.  This fragment is 50 kDa and can bind to 
leukocytes through the normal cross-reactive antigen-90 (NCA-90) [38].  After infusion, 34% of 
99mTc-sulesomab can be detected in the blood after 1 h and at 4 h the radioactivity starts to wash 
out with only 7% of the injected dose remaining in the body after 24 h.  This tracer shows higher 
affinity towards the activated rather than latent granulocytes, thus in vivo radiolabeling is likely 
to occur at the inflammation site rather than to circulating granulocytes [46].  The commercially 
available sulesimab (LeukoScan®) kit comprises of sulesomab, stannous chloride dihydrate, 
potassium sodium tartrate tetrahydrate, sodium acetate trihydrate, sodium chloride, glacial acetic 
acid (trace), hydrochloric acid (trace) and sucrose under the nitrogen.  These lyophilized 
components are reconstituted in a solution of sodium chloride before adding the radioactivity 
with a simple 10 min incubation at room temperature is needed to achieve 99mTc-Sulesimab [47].  





Aside from mainly imaging oncologic abnormalities, 18F-FDG-PET is also a technique to image 
infection and inflammation [48].  The mechanism of 18F-FDG-PET for infection imaging is due 
to an elevated glucose demand by mononuclear and granulocyte cells during their metabolic 
eruption when activated [49-53].  Moreover, glucose is also utilized by proliferating fibroblasts 
[54] but again, this technique cannot distinguish between infection and sterile inflammation.  
Hamacher et al. described a nucleophilic substitution of 18F-fluoride for the synthesis of 18F-FDG 
where they used 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-d-manno-pyranose as a 
precursor (Scheme 1) [55].  The major drawback of this method is the activation of the 18F-
fluoride for the nucleophilic substitution reaction which needs an azeotropic drying step [56]. 




















130 oC, 15 min
Scheme 1. Synthesis of 2-deoxy-2-(18F)fluoro-D-glucose  
2.7. 67/68Ga-Citrate 
The former gold standard of infection imaging, gallium-67 (67Ga) or gallium-68 (68Ga)-labeled 
citrate has been in use as a probe for the last five decades [57].  However, the mechanism of 
uptake of 67/68Ga-citrate is still not entirely clear.  There are several factors which can affect the 
accumulation of this compound around the infection site; this includes direct leukocyte binding, 
complexation to siderophores, or binding to lactoferrin and transferrin [58].  With the advent of 
germanium-68 (68Ge)/Ga/68Ga-generators, 68Gallium-citrate gained momentum as a PET 
radiotracer as it is a more advanced technique than 67Ga-citrate-SPECT.  Rizzello et. al. described 
a method for the preparation of 68Ga-citrate for regular clinical use with a commercial semi-
automatic labeling module (Eckert & Ziegler F-CON Pharmaitalia) [59].  Ayuob et. al. described 
the synthesis where 68GaCl3 (3-5 mCi in 150µl) in 0.6 M HCl was heated to dryness.  A sodium 
citrate solution was added to the dried 68GaCl3 and incubated at 50 °C for 10-15 min followed by 
filtration through a 0.22 micron membrane (Scheme 2).  The final pH of the solution was adjusted 
to 5.5-7 [60].  There is also a kit-based 68Ga-radiolabeling procedure available using ACD as a 
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Table 1 Commercially available probes for infection imaging 
#) FDA approved






Endocarditis, neurological infections, fever of 
unknown origin, diabetic foot, inflammatory bowel 
disease 
72.5 ± 5.5% 
SPECT [62] 
99mTc-HMPAO-leukocyte# 
Imaging of infection and inflammation ( diabetic foot 
prosthetic graft infection, abdominal sepsis, 
osteomyelitis) 
44 ± 13% 
SPECT 
99mTc-Stannous colloids 
Spatial localization of infection for gram-positive 
and gram negative bacteria 
>95% 





Pyrexia of unknown origin, appendicitis, acute 




Pyrexia of unknown origin and infection in soft 
tissues 
4.5% 
SPECT [46]  
Biomolecules 
18F-FDG# 








3. Novel imaging probes for direct, more specific imaging of bacterial infection 
Compounds having affinity towards a specific pathogen can be utilized for its direct in vivo 
imaging after being radiolabeled with a compatible radioisotope.  In 2016, Auletta et al. 
systematically discussed the potential of quinolones, cephalosporins and siderophores as 
promising imaging agents for infection [66].  In a 2015 review, Tsopelos elaborated on 
compounds bearing potential towards scintigraphic detection of infection and inflammation [5].  
Moreover, a few promising tracers show affinity towards bacteria such as 11In-DPC11870, 11In-
DTPA-IgG(14C), 111In/99mTc -DTPA-hpc-IgG, 18F-DPA-714, 99mTc-PEG-liposomes, 99mTc-HAS, 
labelled fMLFKs and labelled interleukins was explained by Tsopelos, however, these molecules 
fall out of the scope of this review.  Furthermore, 99mTc labelled bacteriophages were also omitted 
from this discussion.  The following text highlights selected compound clusters that bear the 
largest potential to accomplish bacteria-selective tomographic imaging: i) antimicrobial peptides 
and ii) biomimetics. 
3.1. Antimicrobial peptides as bacteria-selective imaging probes 
Peptides are short chains of amino acids linked by amide bonds.  These naturally occurring 
biomolecules are logical options for development as possible targeting vectors for PET tracers as 
they have unique characteristics such as; high target specificity and binding ability, low toxicity 
and immunogenicity and easy scale up production in the laboratory [67, 68].  Generally, peptides 
containing less than 50 amino acids are considered for imaging tracers due to their molecular 
weight.  These peptides are relatively small in size, facilitates rapid accumulation at the target 
site as well as lead to faster clearance from the recipient which would make them desirable 
candidates for PET molecular imaging probes [67]. 
In general, naturally occurring peptides are most suited for designing peptide-based PET tracers; 
as they play a vital role in certain physiological conditions by mediating via their high-affinity, 
specific and massively overexpressed receptors [69]. However, various plasma-containing 
proteases and peptidases lead to rapid degradation of some of these compounds resulting in a 
shorter pharmacological half-life and decreased target availability.  Thus, to increase the in vivo 
stability of naturally occurring peptides, these compounds require molecular engineering at the 
amino acid residues that are involved in degradation without compromising the most desired 
biological activity.  Till date, a number of researchers have described various approaches to 
modify amino acid residues to increase the efficiency and stability of peptides.  These approaches 
include peptide bond substitution, N- and C-terminus acetylation, side-chain and unnatural amino 




suitable hydrophilic and/or lipophilic amino acids can also be introduced to modify the 
permeability of the peptide without compromising the binding efficiency [70-72].  
The success of PET probes development is based on identification of its molecular target and 
characterization of its biological role.  Some of the targets best studied for the development of 
peptide-based PET probes are integrin, somatostatin and gastrin-releasing peptide receptors [73-
81].  Moreover, antimicrobial peptides (AMP) are also trending for developing PET tracers for 
infection imaging because of their direct involvement in the innate immune system and their 
ability to bind selectively to pathogenic bacteria or yeast [7, 68].  AMPs are synthesized by 
various cells; however, regardless of the origin, these peptides share a few common 
characteristics as they are membrane active, positively charged and amphipathic [82].  Due to 
their cationic properties, it is believed that AMPs have strong electrostatic affinity towards the 
negatively charged bacterial cell wall while having relatively lower attraction to mammalian cells 
which are less negatively charged [7, 83].  Peptides are becoming popular as infection imaging 
probes because of their ability to accumulate at infection foci as well as a lack of cytotoxicity in 
the recipient [84].  Even though, peptides have been studied extensively as radiotracers for 
various physiological conditions; there is only a handful of AMPs evaluated for infection imaging 
[85].  
3.1.1. Ubiquicidin (UBI) 
Ubiquicidin is a 6.7 kDa polypeptide comprising of 59 amino acid residues.  This peptide was 
first identified from a macrophage cell line of mouse and has antibacterial effects on Salmonella 
typhimurium and Lysteria monocytogenes.  Subsequently it was also isolated from numerous 
organisms, including human.  This peptide has a structure that is homologous to the murine 
ribosomal subunit S30 [86].  Brouwer et al., in 2006, synthesized several fragments of the 99mTc 
labeled UBI and studied the in vitro bacterial sensitivity as well as selectivity.  They also found 
sufficient accumulation of the fragments 99mTc-KVAKQEKKKKKTGRAKRR (UBI-18-35) and 
99mTc-TGRAKRRMQYNRR (UBI29-41) around the infected site in mouse models for SPECT 
imaging [87].  These peptides were synthesized on solid phase via 9-fluorenylmethoxycarbonyl 
(Fmoc) chemistry.  PyBOP was employed as the coupling reagent along with the base 4-
methylmorpholine (NMM) in NMP for the coupling [87].  Direct radiolabeling was carried out 
by adding SnCl2 and sodium pyrophosphate in saline to a stock solution of the peptide.  
Thereafter, KBH4 in 0.1 M NaOH and 99mTc-sodium pertechnetate solutions were added to the 





Scheme 3. Synthesis of 99mTc labeled UBI fragment 
Over the years 99mTc-UBI(29-41) fragments were found to be specific as well as selective towards 
both gram positive and gram negative bacteria along with the multidrug resistant strains [88, 89] 
[90, 91] [92].  99mTc-UBI (29-41) may attach the radioisotope at Lys and Arg residues of the 
peptide.  This did not allow for the peptide to retain its natural configuration [93, 94].  The 
radiolabeled UBI fragment 99mTc-UBI(29-41) was first administered in human subjects in 2004 
for studying its pharmacokinetic properties in a clinical trial on patients with soft-tissue, 
prosthesis or suspected bone infections.  The results revealed high specificity, selectivity and 
accuracy without any significant adverse effects [95].  Recently, fluorine-18 was used to 
radiolabel UBI(29-41) for the purpose of PET imaging.  However in this study, the 18F-UBI(29-
41) did not confirm specificity towards S. aureus in vivo [96] and there was also significant 
defluorination.  Concerning the radiosynthesis, to a mixture of Kryptofix and K2CO3/K2C2O4, 
fluorine-18 was added followed by evaporation under vacuum in the reactor.  Thereafter, 
reduction of the compound was carried out by ethyl 4-(trimethylammonium)benzoate 
trifluoromethanesulfonate in DMSO.  The reaction was heated at 95 °C for 6 min followed by 
the distillation of the product in a 0.5M NaOH solution.  The product was again hydrolysed for 
2 min at 50 °C in the reactor after rinsing it with 5% acetic acid and water.  0.5M HCl was then 
added to make the product 4-18F-fluorobenzoic acid which was eluted through a Lichrolut EN 
cartridge.  A purified solution of this product was mixed with 4-(dimethylamino)-pyridine 
(DMAP) and dried in the reactor.  Subsequently, N,N’-disuccinimidylcarbonate (DSC, in 
acetonitrile) was added and heated at 95 °C for 7 min followed by cooling to 35 °C.  This crude 
N-succinimidyl-4-[18F]fluorobenzoate was eluted through a Lichrolut EN cartridge followed by 
HPLC purification and again eluted through a Lichrolut EN cartridge.  Finally, the N-
succinimidyl-4-[18F]fluorobenzoate (in DMF) was mixed with UBI 29-41 in 0.1M boraxbuffer 
(pH 8.5) and left to react for 10 min at room temperature in a ultrasound bath.  The radiolabeled 
4-[18F]fluoro-benzoyl-ubiquicidin 29-41 (18F-UBI29-41) was HPLC purified followed by elution 











Scheme 4. Synthesis of [18F]UBI 29–41 
68Ga-NOTA-UBI(29-41) showed specificity towards S. aureus in a rabbit model and was able to 
distinguish infection from sterile inflammation [98].  For the design of the UBI containing the 
68Ga radiotracer, a chelator was envisaged.  In this case the peptide was synthesized on resin and 
conjugated with 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA).  The NOTA conjugation 
was carried out by functionalizing the amino terminus of the peptide with bromoacetic acid and 
diisopropylcarbodiimide (DIC) in dichloromethane.  The bromine was then displaced with excess 
1,4,7-triazacyclononane and trimethylamine (TEA) in acetonitrile.  tert-Butyl 2-bromoacetate 
was added to the remaining secondary amines of triazacyclononane ring [98] followed by full 



























































Scheme 5. Synthesis of 68Ga-NOTA-UBI29-41 complex 
3.1.2. Human neutrophil peptide (HNP) 
Neutrophils are integral components of the immune system and play a vital role in protecting the 
host from microbial infections by producing neutrophil peptides.  These cationic single chain 
peptides are rich in arginine and cysteine.  Neutrophil peptides are of about 3.5 kDa and 
designated as defensins [99].  HNP-1, HNP-2, HNP-3 and HNP-4 are the four neutrophil peptides 




















95 oC, 6 min






residues which represents 99% sequence homology while HNP-4 shares only 32% homology 
with the others [101, 102].  HNP-1 is one of the more extensively studied antimicrobial peptides 
found in the defensin family.  It is postulated that defensin interact with deoxyribonucleic acids, 
which in turn leads to cell death [103].  Mouse infection model studies revealed the potential use 
of HNP-1 as a therapeutic agent for bacteria including M. tuberculosis [104].  Biodistribution 
and potential antimicrobial evaluation of 99mTc labelled HNP-1 in K. pneumoniae and S. aureus 
infected (peritoneal and intramuscular infections) swiss mice confirms the accumulation of this 
tracer in the infection sites [105].  In this study, Welling et. al. isolated HNP-1 from human 
neutrophil, which was then purified by HPLC [105].  HNP-1 in sodium phosphate buffer (Na-
PB) was then mixed with a sterile solution of stannous pyrophosphate and immediately reduced 
with KBH4 dissolved in a NaOH solution.  Finally, the solution was stirred for 30 min with 99mTc-
sodium pertechnetate solution to yield radiolabelled HNP-1 [105-107].  Raj et. al., in 2000, 
described a method for the solid phase synthesis of HNP-1 on Wang resin using Fmoc protected 
amino acids [108].  DIC in the presence of HOBt was used as the coupling reagent where a 
mixture of DCM and DMF (50% v/v) served as the solvents.  Fmoc deprotection was carried out 
using 25% solution of piperidine in DMF and the peptide was cleaved from the resin using 90% 
TFA in DCM containing dimethyl sulphide (2.5%) and thioanisole (2.5%) [108]. 
3.1.3. Neutrophil elastase inhibitor peptide 
The protease, neutrophil elastase is secreted by the activated neutrophils when triggered due to 
inflammation at the infection foci.  This 29 kDa antimicrobial peptide is released upon 
internalization [109] and rapidly inhibited by α-1 trypsin inhibitor [110].  A peptide library was 
constructed based on wild-type bovine pancreatic trypsin inhibitors with the help of phage 
display technology.  Screening of these peptides on immobilized human neutrophil elastase, 
revealed EPI-HNE-2 as the most potent and specific inhibitor [111, 112].  EPI-HNE-2 
radiolabeled with 99mTc was studied in monkeys for inflammation/infection imaging.  Based on 
the outcome, the bacterial specificity of the tracer was not clear, however, it did accumulate 
within areas with inflammations and infections [113].  EPI-HNE-2 can be radiolabeled with 99mTc 
using the bifunctional chelator molecule NHS-MAG3.  Peptide-NHS-MAG3 conjugation was 
carried out by a dropwise chelator addition (in DMF) to a solution of EPI-HNE-2 in 0.1 M 
HEPES buffer (pH 8.0).  The solution was then left for 1 h undisturbed and finally the conjugated 
peptide was purified on a P-4 column (Bio-Rad, Melville, NY).  To the purified conjugated 
peptide in 0.25 M ammonium acetate buffer, sodium tartrate (in 0.5 M sodium bicarbonate), 
ammonium acetate and ammonium hydroxide was added followed by a solution of stannous 




room temperature for the completion of the reaction (Scheme 6).  The pH was adjusted to 7.6 
and purified on a P-4 column [114].  
 
Scheme 6. Synthesis of 99mTc-MAG3-EPI-HNP2 
3.1.4. Human β-defensin (HBD) 
Defensins are the first line of the defense mechanism of the human immune system and the β 
defensins are one class that are of epithelial tissue origin [115, 116].  A 4 kDa peptide, human β 
defensin-3 (HBD-3), shows a broad range of antimicrobial activity including for both gram-
positive and -negative bacteria [117-119].  HBD-3 was successfully radiolabeled with 99mTc and 
was able to distinguish between infection and sterile inflammation in a mouse model previously 
infected with S. aureus [115].  A cationic complex [99mTc (H2O)3(CO)3]+ was used to label the 
recombinant HBD-3 [115].  [99mTc (H2O)3(CO)3]+ can be synthesized through the reduction of 
[99mTcO4]- in saline (0.9% NaCl/H2O) by NaBH4.  This reaction required heating at 75 °C and 
flashed with carbon monoxide [120].  The solution was cooled and adjusted to pH 8.0 with HCl.  
The peptide, dissolved in water, was added to the solution containing [99mTc (H2O)3 (CO)3]+ and 
left for 60 min to react at room temperature (Scheme 7).  The radiolabeled HBD-3 was finally 
purified by gel chromatography using a Sephadex G-2 column [115].  
 












3.1.5. Human lactoferrin-derived peptide (hLF) 
Lactoferrin, a member of the transferrin family, is an 80 kDa iron-binding protein [121, 122].  
This glycoprotein is secreted by mammalian mucosal epithelial cells including those of human 
[122].  Lactoferrin is found in milk, urine, bile, nasal and bronchial secretions, gastrointestinal 
fluids, semen, vaginal fluids, tears and saliva [123-125].  The defensive properties of this peptide 
includes antimicrobial (including antibiotic-resistant bacteria), anti-inflammatory and anticancer 
properties due to immune modulator activities [122, 126].  An eleven amino acid containing 
cation-rich sequence (1-11: GRRRRSVQWCA) from the N-terminus of human lactoferrin was 
reported to be active against bacteria and also showed immune modulatory compound behaviour 
[126, 127].  Welling et. al. in 2000, studied various fragments of UBI and hLF for their bacterial 
specificity and selectivity; concluding that the former is more favourable for infection detection 
[92].  For this study the peptide sequences were synthesized on solid phase employing Fmoc 
chemistry with PyBOP/NMM in NMP as coupling conditions with Fmoc deprotection using 
piperidine [128].  For radiolabelling, the synthesized peptide solutions (in 0.01 M of acetic acid 
pH 4) were mixed with stannous pyrophosphate followed by immediate addition of KBH4 (in 0.1 
M NaOH).  Finally a 99mTc-sodium pertechnetate solution obtained from a 99mTc generator was 
added and the pH was adjusted to between 5-6.  One hour of gentle stirring was carried out for 
completion of the reaction (Scheme 8) [92]. 
  















Table 2 Antimicrobial peptides for bacterial imaging 
*) UBI29-41:ubiquicidin peptide fragment 29-41 ;HNP-1: human neutrophil peptide 1; EPI-HNE-2: Neutrophil elastase inhibitor peptide 2;  HBD-
3: human β defensin-3; hLF: human lactoferrin-derived peptide 1-11 
^) S. aureus: Staphylococcus aureus; E. coli: Escherichia coli; C. albicans: Candida albicans; A. fumigatus: Aspergillus fumigatus; K. pneumonia: 
Klebsiella pneumonia; M. tuberculosis: Mycobacterium tuberculosis 

















S. aureus, E. coli, C. albicans and A. 
fumigatus 
2.2-4.6  >95% -  99.2%   
Scintigraphy, 
PET,   
[89, 96, 98] 
HNP-1 99mTc K. pneumonia, S. aureus,  M. tuberculosis 1.5-3.5 88% Scintigraphy [105] 
EPI-HNE-2 99mTc -- 0.3-2 54% Scintigraphy [113, 114] 
HBD-3 99mTc S. aureus,  K. pneumoniae and E. coli 3 40% - 50% Scintigraphy [115] 





Biomimetics are a group of compounds that are deliberate to exploit unique bacterial targets.  
These compounds are trapped upon internalization either because of their interaction with the 
cellular macromolecules or by acting as a substrate for the enzyme of the pathogen.  This 
intracellular mechanism in turn promises for signal amplification and allows for imaging of the 
pathogen. 
3.2.1. Antibiotics/Antimicrobial drugs 
Antibiotics are potential candidates for tomographic imaging because of their characteristic 
specificity towards bacteria.  99mTc-ciprofloxacin is the first and most widely studied radiolabeled 
antibiotic [129-132].  99mTc-fluoroquinolones (99mTc-norofloxacin, 99mTc-sparfloxacin) were 
subsequently explored as a second line of antibiotic based radiotracer.  Evidently, the potential 
of other antibiotics has been investigated as imaging agents; for example, intracellular targets 
(99mTc-kanamycin, 99mTc-cefuroxineaxetil, 99mTc-cefoperazone, 99mTc, -ceftizoxine), cell wall 
(99mTc-vancomycin, 99mTc-alafosfalin, 99mTc-ceftizoxine) and specific mycobacterial targets 
(11C/99mTc-rifampicin, 11C/18F/99mTc-isoniazid and 99mTc-ethambutol). 
3.2.1.1. Aminoglycoside 
Aminoglycosides are polycationic entities which manifests its effect by ribosomal blockade, 
misreading in translation, membrane damage, and irreversible uptake of the antibiotic [133, 134].  
Labelling of kanamycin, streptomycin and gentamicin can be achieved with the reducing agent 
SnCl2(2.H2O).  A solution of SnCl2 was added to a solution of 
kanamycin/streptomycin/gentamicin and the pH adjusted.  To that mixture, 99mTcO4 – was added 
and the reaction was carried out at room temperature (Scheme 9) [135-137].  For the labeling of 
tobramycin, the same reducing agent was utilised but with the exception that the SnCl2(2.H2O) 
was dissolved in HCl and then mixed with a solution of NaOH:NaHCO3 and Na99mTcO4 under a 

























































Kanamycin A NH2 OH
Kanamycin B NH2 NH2
Kanamycin C OH NH2
pH = 9, r.t, 30 min
 
Scheme 9. Synthesis of 99mTc-Kanamycin  
3.2.1.2. Amino-penicillin 3rd generation 
As a member of the amino-penicillin group of drugs, amoxicillin acts against gram-positive and 
gram negative bacteria by interfering with the cell wall muco-peptide biosynthesis [139].  99mTc- 
amoxicillin has demonstrated to be taken up by E. coli infected and inflamed thigh muscles in an 
animal model [140].  Amoxicillin was radiolabeled with 99mTc by Ozdemir et. al. in 2015 [140].  
They demonstrated the use of both the reducing agent and antioxidant for labeling amoxicillin.  
Amoxicillin was mixed with stannous chloride under an atmosphere of nitrogen and radiolabeling 
was initiated by adding freshly eluted 99mTc.  The improvement of labeling efficiency and 
stability of the complex was judged by addition of the antioxidant (ascorbic acid) to the solution. 





































pH = 4.8-7.4, r.t, 15 min
 
Scheme 10. Synthesis of 99mTc- amoxicillin 
3.2.1.3. Cephalosporins  
The 𝛽-lactam group of antibiotics compromises the bacterial cell wall integrity by hampering the 
peptidoglycan layer synthesis [5].  A few of the cephalosporins that have been radiolabeled so 
far are cefuroxine, ceftizoxine, ceftriaxone, cefotaxime, cefoperazone and cefepime.  These 
antibiotics complexed with 99mTc showed potential advantages in distinguishing infection (S. 




Cephalosporins such as cefuroxine axetil, ceftriaxone and cefepime were radiolabelled in the 
presence of the reducing agent stannous chloride.  The compound was dissolved in sterile water, 
mixed with a solution of SnCl2(2.H2O) and the pH was adjusted.  Finally Na99mTcO4 was added 
to the solution and incubated at room temperature [141-143].  However in the case of ceftriaxone, 








































pH = 7.0, ref lux (5-10 min), r.t (10 min)
Scheme 11. Synthesis of 99mTc-ceftriaxone  
For radiolabeling ceftizoxima and cefotaxime, the compounds were dissolved in water and 
sodium dithionate (dissolved in 0.5% NaHCO3) was added followed by 99mTc-pertechnetate.  The 
solutions were heated to 100 °C before maintaining it at room temperature [144, 145]. 
In the case of cefoperazone, the antibiotic was mixed with a tin(II) solution and the pH was 
adjusted.  Finally, freshly eluted 99mTc-activity was added to the mixture and incubated at room 
temperature with vigorous shaking until completion of the reaction [146]. 
3.2.1.4. Glycopeptides 
Teicoplanin and vancomycin fall under the glycopeptide group of antibiotics with their mode of 
action by interfering with the peptidoglycan layer synthesis [147]. Radiolabeled 99mTc-
teicoplanin was shown to accumulate in high concentration (in 2 h) at the site of S. aureus in 
infected mice [148].  In another study, 99mTc-vancomycin also showed similar affinity towards 
S. aureus infection foci [149].  Glycopeptides, vancomycin and teicoplanin, were radiolabeled in 
the presence of SnCl2.H2O.  Briefly, the glycopeptide was mixed with SnCl2.H2O and the pH was 
adjusted.  The solution was incubated at room temperature after addition of a freshly prepared 
solution of 99mTcO4− [148, 149].  
3.2.1.5. Lincosamide 
Lincosamide binds to the 50S subunit of bacterial ribosomes and blocks the exit of the newly 
formed peptide [150].  The lincosamide group of antibiotics, namely clindamycin and 
lincomycin, were radiolabeled in the similar way as described above. 99mTc-lincomycin was 
studied in a rabbit model, which showed significant accumulation of this labeled antibiotic in S. 
aureus infected thigh [151].  In another study 99mTc-clindamycin showed its potential to 




Antibiotics were mixed with SnCl2.2.H2O and the pH was adjusted.  Ascorbic acid was added to 
the reaction mixture as a stabilizer followed by freshly eluted 99mTcO4− [151, 152].  
3.2.1.6. Macrolides 
Macrolides, though structurally different from lincosamide antibiotics share the same mechanism 
of action by also binding to the 50S subunit of the bacterial ribosome [150].  Erythromycin, 
clarithromycin and azithromycin, as the group-representing compounds, were successfully 
radiolabeled with 99mTc.  These probes were subsequently studied in a mouse model to evaluate 
their potential as radiopharmaceutics.  In these studies, radiolabeled 99mTc-clarithromycin and 
99mTc-azithromycin significantly accumulated in the S. aureus infected thigh compared to the 
uninfected contralateral thigh.  Solutions of the macrolide class of antibiotics (erythromycin, 
clarithromycin and azithromycin) were mixed with SnCl2.2.H2O and pH was adjusted with HCl.  
99mTcO4− was added to the mixture and the reaction was carried out at room temperature [153-
155]. 
3.2.1.7. Nitrofurans 
The mode of action for nitrofurans is by targeting and damaging the deoxyribonucleic acid 
(DNA) of the pathogen in its reduced form.  Nitrofuran is reduced by the flavoproteins of the 
pathogen into reactive intermediates which in turn affects the pyruvate metabolism, respiration 
and ribosomal DNA [156].  Nitrofurantoin was successfully radiolabeled with 99mTc for potential 
imaging of E. coli.  It was labeled with sodium pertechnetate in the presence of stannous chloride 
(Scheme 12) [157]. 
 
Scheme 12. Synthesis of 99mTc-Nitrofurantoin 
3.2.1.8. Oxazolidinones 
Linezolid is an oxazolidinone-type antibiotic that inhibits the bacterial protein synthesis initiation 
and shows activity against gram-positive microorganisms [158].  Iodine-131-(131I)-linezolid was 
proven to be used for imaging S. aureus in a rat model.  In the bacterial infected foci, the 































sites in 30 min.  In order to radiolabel linezolid with131I, to an iodogen coated vial, a linezolid 
solution was added followed by Na131I and incubation at room temperature.  Finally, Na2SO3 was 























Scheme 13. Synthesis of 131I-Linezolid 
3.2.1.9. Fluoroquinolones 
Fluoro-quinolones prevent the DNA synthesis of bacteria by interacting with the DNA gyrase 
which eventually restricts uncoiling of DNA [5].  A large number of compounds in this group of 
antibiotics were radiolabeled with 99mTc, 18F and 68Ga for radiopharmaceutical studies.  As 
recently reviewed, PET or SPECT imaging using radiolabeled quinolones distinguished between 
infection and inflammation in various infected animal models as well as in human subjects.  
Radiolabeling procedures with 99mTc were used to study the potential of fluoroquinolones as 
imaging probes and included ciprofloxacin, enrofloxacin, difloxacin, perfloxacin, lomefloxacin, 
ofloxacin, rufloxacin (Scheme 14), norfloxacin, danoflaoxacin, sparfloxacin, levofloxacin, 
moxifloxacin (Scheme 15), gemifloxacin (Scheme 16), garenoxacin (Scheme 17), clinafloxacin 
(Scheme 18), gatifloxacin and trovafloxacin [131, 143, 157, 160-172].  Radiolabeling for these 
antibiotics was carried out with SnCl2(2.H2O) and 99TcO4- with the exception for enrofloxacin 
where stanous tartrate was used.  However, in case of levofloxacin and gemifloxacin (Scheme 
16) sodium pertechnetate was used in place of 99TcO4-.  The antibiotics ciprofloxacin, fleroxacin 
and trovafloxacin were also radiolabeled with 18F.  For the synthesis of 18F-fleroxacin; 6,7,8-
trifluoro-1,4-dihydro-1-(2-hydroxyethyl)-4-oxo-3-quinolinecarboxylic acid ethyl ester was 
produced by alkylating 6,7,8- trifluoro-4-hydroxyquinoline-3-carboxylic acid ethyl ester by 2-
bromoethanol.  This was followed by condensation with 1-methyl-piperazine which yielded 6,8-
difluoro-1,4-dihydro-1-(2-hydroxyethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-3-
quinolinecarboxylic acid ethyl ester.  The reaction was followed by the addition of 




form of 18F, in the presence of Kryptofix, substituted the mesylate followed by basic hydrolysis 
resulting in the synthesis of 18F-fleroxacin [173].  In the case of trodoxacin labeling; 18F was dried 
in the presence of K2CO3 and Kryptofix.  To this mixture trodoxacin in DMSO was added and 
heated to yield the radiolabeled product [172].   
 
Scheme 14. Synthesis of 99mTc-Rufloxacin 
 




















pH = 5.4, r.t, 30 min
















































































Scheme 18. Synthesis of 99mTc(CO)3-Clinafloxacin 
Ciprofloxacin was also successfully radiolabeled with 68Ga.  Ciprofloxacin propyl amine was 
reacted with p-SCN-Bz-DOTA or p-SCN-Bz-NOTA to produce the DOTA- and NOTA-
conjugates of ciprofloxacin, respectively.  Radiolabeling was conducted by incubating 68Ga with 























































pH = 9, r.t, 24 h
p-SCN-Bz-NOTA
pH = 9, r.t, 24 h
68Ga in NaOAc buffer




















68Ga in NaOAc buffer













Scheme 19. Synthesis of 68Ga-DOTA-Ciprofloxacin and 68Ga-NOTA-Ciprofloxacin 
3.2.1.10. Anti-mycobacteria 
Rifampicin (Scheme 20) and ethambutol (Scheme 21) were radiolabeled with 99mTcO4
- 
in the presence of SnCl2(2.H2O) or stannous tartrate, respectively [175, 176]; however, 
99mTc–isoniazid was synthesized by utilizing co-ligands tricine and ethylenediamine-
































O NaOH, TFA, 0 oC, 15 min







carbon-11 (11C)-radiolabeling procedures are reported for rifampicin and pyrazinamide.  
The rifampicin piperazine moiety was radiolabelled with 11CCH3I in the presence of 
potassium carbonate as the base in a mixture of DMSO and ACN as solvents (Scheme 
23) [178].  The synthesis of 11C-isoniazid and 11C-pyrazinamide were initiated by 
reacting iodopyridine and 2-iodopyrazine with 11C-HCN respectively in the presence of 
the catalyst tetrakis(triphenylphosphine)palladium (0).  In case of isoniazid, cyanide was 
hydrolyzed by hydrazine and the subsequent imine was hydrolyzed by water (Scheme 
24).  However, in case of pyrazinamide, the cyano-group of the product 11C-
cyanopyrazine was hydrolyzed by hydrogen peroxide under basic conditions to yield 




























pH = 5.6, r.t













































Scheme 23. Synthesis of 11C-rifampicin 
 
 
Scheme 24. Synthesis of 11C-Isoniazid 
 
 
Scheme 25. Synthesis of 11C-pyrazinamide 
3.2.1.11. Tetracyclines 
The mode of action with tetracycline antibiotics prevents the binding of the aminoacyl-tRNA to 
the ribosomal acceptor (A) site thereby inhibiting the protein synthesis [179].  One of the 
radiolabeled antibiotics from this group, 99mTc-doxycycline was explored in an E. coli-infected 
rat model.  The study revealed a rapid accumulation of this radiotracer in the infected site and 
could easily be distinguished from the soft tissue.  Doxycycline was radiolabeled with 99mTc in 

































































135 oC, 5 min
H2O2, 0.1M K2CO3






















Aminoglycoside Kanamycin 99mTc Some Gram-negative bacteria, 
Staphylococci and M. tuberculosis 
2.5 95.0% --  [136] 
Tobramycin 99mTc - -- Gamma camera [138] 
Gentamicin 99mTc - 96.9%  Gamma counter [137] 
Streptomycin 99mTc 2.4 98.0% SPECT [135] 
Amino-
penicillin  
Amoxicillin 99mTc Susceptible Gram-positive and Gram-
negative bacteria 




Isoniazid 99mTc and 18F Mainly M. tuberculosis and a few Gram-
positive bacteria 
1.3 -- PET/CT [181] 
Ethambutol 99mTc - >85.0% SPECT [175] 
Rifampicin 99mTc and 11C 7.3  Gamma camera,  PET [178] 
Pyrazinamide 11C - 99.0% PET [178] 
Cephalosporins  Cefuroxine 99mTc Susceptible Gram-positive and -negative 
bacteria  
2.5 98.0% Cd(Te) detector [141] 
Ceftizoxine 99mTc Susceptible enteric Gram-positive and -
negative bacteria incl. H. influenza 
3.2 94.9%  Gamma camera [144, 182] 
Ceftriaxone 99mTc 5.6 96.0% Gamma camera [142, 183] 
Cefotaxime 99mTc 3.0 92.0% Planar scintigraphy [145] 
Cefoperazone 99mTc 4.5 97.9% γ-scintillation counter [146] 
Cefepime 99mTc Extended spectrum of Gram-positive and -
negative bacteria 
8.4 98 ± 1.4 % -- [143] 
(Fluoro)-
Quinolones  
Ciprofloxacin 68Ga, 18F and 99mTc Susceptible Gram-positive and -negative 
bacteria and fungi 
1.8-5.5 85.0-90.0% / 
81±4% 
PET,  Scintigraphy [131, 160, 174, 184, 185] 
Difloxacin 99mTc 5.5 95.6 % NaI(Tl) detector [162] 
Perfloxacin 99mTc 4.9 98.1% NaI(Tl) detector [162] 
Lomefloxacin 99mTc 6.5 93.6% γ-scintillation counter [163] 




Rufloxacin 99mTc 6.0 98.10 ± 
0.18% 
Well counter interface with 
scalar count rate meter 
( WCSCR) 
[164] 
Norfloxacin 99mTc 6.9 95.4% Scintigraphy [165, 186] 
Danoflaoxacin 99mTc 7.2 90 ± 2% Well-type c-scintillation 
detector 
[166] 
Sparfloxacin 99mTc Many Gram-positive and Gram-negative 
bacteria  
5.9 >95% Gamma camera [167] 
Levofloxacin 99mTc 7.2  99.74% Scintigraphy [168] 
Fleroxacin 18F 1.3 5-8% PET [173] 
Moxifloxacin 99mTc Susceptible Gram-positive and Gram-
negative bacteria  
incl. Methicillin-resistant S. aureus 
(MRSA) and  
Penicillin-resistant Streptococci stains 
(PRSC) 
6.8 --  WCSCR [169] 
Gemifloxacin 99mTc 4.9 -- Single well counter interface 
with scalar count rate meter 
[187] 
Clinafloxacin 99mTc 5.0 -- Single well counter fitted with 
a scalar count rate meter 
[170] 
Garenoxacin 99mTc 5.4 98.25 ± 
0.22% 
WCSCR [171] 
Gatifloxacin 99mTc 4.5 90 ± 1.8% -- [143] 
Trovafloxacin 18F  and 99mTc 6.0 15-30% PET [172] 
Glycopeptide Vancomycin 99mTc Susceptible Gram-positive bacteria incl.  
Methicillin-resistant S. aureus (MRSA) 
and E. faecalis 
5.0 > 95% Gamma counter [8] 
Teicoplanin 99mTc 4.3 87.7 ± 1.3% Scintigraphy [148, 188] 
Lincosamide Clindamycin 99mTc Susceptible Gram-positive and Gram-
negative bacteria 
3.1 > 95% Scintigraphy 85 [152] 
Lincomycin 99mTc 3.0 > 98% Scintigraphy 86 [151] 
Macrolides Azithromycin 99mTc Gram-positive-, some Gram-negative- and 
atypical bacteria. 
6.2 97.5 ± 0.9% -- [153] 
Erytmocytin 99mTc 2.4 >98% Scintigraphy [155] 
Clarithromyci
n 









Nitrofuratoin 99mTc Susceptible Gram-positive and Gram-
negative bacteria 
7.3 97.50 ± 
0.16% 
Scintigraphy [157] 
Oxaolidinones Linezolid 131I  Susceptible Gram-positive and Gram-
negative bacteria 
77.48 85 ± 1%  Cd(Te) detector [159] 
Tetracyclines Doxycycline 99mTc All medically relevant aerobic and 
anaerobic bacteria  




-- Scintigraphy [180] 
a)  Bacteria targeted based on the antibiotics class preferences (not the radiolabeled equivalent), some candidates may divert slightly in their sensitivity 
or specificity towards single types of bacteria. 







3.2.2.1. Biotin (Vitamin H) 
Biotin is an essential growth factor for some bacteria and is required for the metabolism of amino 
acids and fats.  It also is involved in the production of fatty acids [189].  111In-labeled biotin 
demonstrated avid uptake in cultures of S. aureus [190].  Radiolabeled biotin also showed 
selectivity and specificity towards spinal infections in patients [191].  Biotin radiolabeling has 
been reported using the bifunctional chelator molecule diethylenetriaminepentaacetic acid 
(DTPA).  Commercially available DTPA-Biotin was incubated with 111In-chloride at room 
temperature for optimal radiolabeling [190, 191].  DOTA-functionalized biotin was also 
successfully labeled with 68Ga (buffered with HEPES).  68Ga-complexations were conducted at 
both at room and elevated (90 °C) temperatures (Scheme 26) [192]. 
 
Scheme 26. Radiosynthesis of 68Ga-DOTA-Biotin 
3.2.2.2. Cyano-cobalamin (CBL) 
Cyano-cobalamins are transported by cobalamin transport proteins.  These proteins have 
antagonistic effects against bacterial growth and colonization; and are found in salivary glands 
and secondary granules of granulocytes [193].  Baldoni et. al. reported on the rapid in vitro 
specificity of the CBL derivative 99mTc-PAMA(4)-CBL towards S. aureus and E. coli [194].  
Waibel et. al. demonstrated the synthesis and radiolabeling of 99mTc-PAMA-CBL [195]; Cbl-b-
acid (obtained by the controlled acid hydrolysis of cyano-cobalamin in 0.1 mol/L HCl) was 
coupled with Boc-deprotected PAMA using coupling reagents, either 1-(3-
dimethylaminopropyl)-3-ethylcarbodimide hydrochloride or 2-(1H-benzotriazole-1-y1)-1,1,3,3-
tetramethyluronium tetrafluoro-borate, to synthesize Cbl-b-(ethyl-hexyl)-PAMA-OEt.  To 
achieve optimal radiolabeling, [99mTc(CO)3(OH2)3]+ was prepared using the isolink kit by heating 
[Na][99mTcO4].  Cbl-b-(ethyl-hexyl)-PAMA-OEt was then incubated with [99mTc(CO)3(OH2)3]+ 
in 2-(N-morpholino)ethanesulfonic acid (MES) buffer at 75 °C under a nitrogen environment 
[194, 195]. 
3.2.3. Aptamers (Oligomers) 
Aptamers are a rather novel class of compounds with potential as radiopharmaceutics because of 




a specific target [196] such as cell surface pathogen-specific proteins or bacteria-specific 
receptors [197].  S. aureus specific aptamers SA20, SA23 and SA34 were successfully labeled 
with 99mTc, which showed high uptake in the infected site (S. aureus) compared to the muscle 
infected with C. albicans and zymosan developed inflammation [198].  The radiolabeling was 
carried out by adding tricine, EDDA into 0.9% saline and the aptamers followed by the addition 
of SnCl2.2H2O.  After adjusting the pH to 7, the reaction vessel was sealed and a vacuum was 
created.  99mTcO4− was added and the mixture refluxed to facilitate the radiolabeling (Scheme 27) 
[198].  
 
Scheme 27. Principle of direct 99mTc-radiolabeling of aptamers 
Chen et. al. demonstrated the specificity of the radiolabeled oligomers towards the RNA of S. 
aureus, K. pneumoniae and E. coli [199].  The oligomers that were investigated included 
phosphorodiamidate morpholino (MORF), peptide nucleic acids (PNA), and phosphorothioate 
DNA (PS-DNA) that were conjugated with NHS-MAG3 [200].  The MAG3-conjugated oligomers 
were mixed with a solution of ammonium acetate, tartrate and freshly prepared SnCl2.2H2O (in 
HCl/ ascorbate) and vortexed.  Finally, 99mTcO4− was added and the mixture was heated at 95 °C 
(Scheme 28) [199].  In another example, the same group demonstrated that the 12-mer 
phosphorodiamidate morpholino (MORF) oligomer, that was complementary to bacterial 
ribosomal RNA, was specific in its identification of K. pneumoniae in infected mouse muscles 
[201].  Radiolabeling was carried out in the similar manner as described above.  
 
Scheme 28. Synthesis of 99mTc-NHS-MAG3-(MORF/PNA/PS-DNA) 
3.2.4. Puromycin 
Puromycin is a protein synthesis inhibitor that affects the derivatization of immature polypeptide 
chains as polypeptidyl-puromycin [202].  Eigner et. al. emphasised the potential of 68Ga-DOTA-



























synthesis of the microbial colonies [203].  The study revealed that there is no accumulation of 
the radiotracer in sites of sterile inflammation; however, high contrast µPET/CT images were 
obtained in the subcutaneous colonies of S. aureus infected foci [203].  The investigators used 
commercially available DOTA-Pur for radiolabelling with 68Ga.  Briefly, DOTA-Puromycin was 
added to a solution of freshly eluted 68Ga (in HCl) after pH adjustment and the reaction mixture 
was incubated at 95 °C until completion followed by purification through a Strata-X column 
[203]. 
3.2.5. Radiolabeled purines and pyrimidines 
Herpes simplex virus 1 (HSV1) thymidine kinase (TK) is an important enzyme for the transfer 
of a phosphate group to the 5ʹ hydroxyl group of pyrimidines from ATP.  HSV1-TK reporter 
gene system can be of importance as its substrate can be radiolabeled for tracing.  These 
radiotracers are subsequently phosphorylated and cellularly trapped upon introduction of the 
charge of the phosphate group [204].  This mechanism was successfully implemented in 
transformed tumor cells imaging and based on this fact it was approached for imaging TKs of 
bacteria in mammals [205].  Bettegowda et. al. demonstrated the selectivity of iodine-125 (125I)-
radiolabeled 1-(2ʹ-deoxy-2ʹ-fluoro-5-iodo-1-β-D-arabinofuranosyl) -5-iodouracil (FIAU) 
towards TK of a wild-type E. coli strain [205].  Subsequent studies on 125I-FIAU revealed its 
application for imaging musculoskeletal infections in patients [206].  For radiolabeling, 1-(2ʹ-
deoxy-2ʹ-fluoro- β -D-arabinofuranoside)-uracil (FAU) was dissolved in HNO3 and to this 
solution 125I-NaI was added.  The reaction was heated at 130 °C and finally quenched with a 


















Scheme 29. Synthesis of 125I-FIAU 
3.2.6. Glycopyranose derivatives 
Bacteria can utilize unique sugars such as maltose, sorbitol and trehalose as energy sources.  
However, mammalian cells are deficient in the transporters for these molecules which may bear 
great potential as probes for bacterial imaging [207].  The maltose derivatives 6-18F-
fluoromaltose and 18F-maltohexanose (18F-MH) have been synthesized and reported to be 
bacterial specific [208-210].  6-18F-fluoromaltose was reported to be taken up by both gram 
positive as well as gram negative bacteria; however, insignificant amounts were detected in tumor 




showing minimal affinity towards mammalian cells [210].  For the synthesis of 6-18F-
fluoromaltose; 18F-fluoride was eluted with a solution of K2CO3 and Kryptofix in water and 
acetonitrile.  An anhydrous residue was obtained after evaporation of the solvent, which was then 
added to a 1,2,3-tri-O-acetyl-4-O-(2ʹ,3ʹ,-di-O-acetyl-4ʹ,6ʹ-benzylidene-α-D-glucopyranosyl)-6-
deoxy-6-O-nosyl-D-glucopranosidic solution in ACN followed by heating at 80 °C.  This 
intermediate compound was purified using a C-18 Sep-Pak cartridge.  The purified product was 
then first hydrolyzed by HCl at 110 °C followed by addition of NaOH at room temperature to 

































Scheme 30. Synthesis of 6-18F-fluoromaltose 
Radiochemical synthesis of 18F-MH was obtained by cryptate-mediated nucleophilic substitution 
of maltohexose-brosylate precursor with K18F (in ACN, at 110 °C).  The compound synthesized 
was then hydrolyzed with NaOH (in water, at 110 °C) followed by acid neutralization at room 























































1. [18F]-KF/Kryptofix, CH3CN, 110
oC
2. NaOH, H2O, 110
oC
3. HCl, H2O, r.t
 
Scheme 31. Synthesis of 18F-maltohexanose 
Sorbitol is considered as a probe towards the identification of enterobacteriaceae because this 
class can selectively metabolize glycopyranose using the glycerol diffusion facilitator (glpF).  
The radiolabeled sorbitol derivative 18F-fluorodesoxysorbitol (18F-FDS) is reported to be target 
specific and also capable of identifying drug resistance [211-213].  18F-FDS can be synthesized 





















18F-FDG 18F-FDS  
Scheme 32. Synthesis of 18F-fluorodesoxysorbitol 
The non-mammalian disaccharide trehalose is utilized by bacteria for stress protection, 
carbohydrate storage and even an energy source.  It is also a constituent of the cell wall of some 
mycobacteria [214].  A trehalose derivative, 2-fluorotrehalose (2-FDT)-PET/CT, was 
successfully applied for the detection of tubercular lesions in a rabbit infection model bearing 
Mycobacterium tuberculosis HN878 [215].  The 2-fluorotrehalose (2-FDT) synthesis is a 
biomimetic process, inspired by the bacterial synthesis of trehalose from glucose.  Chemo-
enzymatic synthesis of 2-FDT occurs as a one-pot cascade reaction in which hexokinase transfers 
a phosphate from adenosine triphosphate (ATP) to 18F-FDG (normally glucose in bacterial 
trehalose synthesis).  OtsA then transfers the glucose from the donor UDP-glucose to the acceptor 
phosphorylated 18F-FDG.  Dephosphorylation gives the desired product that is affected by OtsB.  
The entire one-pot process is complete in 45 min.  
Amino sugars are one of the essential components of the bacterial cell wall.  In both gram 
negative and gram positive bacteria, they form the peptidoglycan backbone.  Bacterial cell walls 
are composed of alternate sequences of N-acetylglucosamine and N-acetylmuramic acid, joined 
by oligopeptides.  The use of N-acetylglucosamine as a radiotracer by incorporating a 
radioisotope bears potential hope for bacterial imaging.  Martínez et. al. described the synthesis 
and application of 2-deoxy-2-(18F)-fluoroacetamido-D-glucopyranose (18F-FAG).  They were 
capable of successfully identifying E. coli in infected rat models.  The synthesis of 18F-FAG was 
carried out by using 1,3,4,6-tetra-O-acetyl-2-deoxy-2-bromoacetamido-D-glucopyranose as a 
precursor with microwave heating.  18F-fluorine eluted in a solution of K2CO3/ Kryptofix and 
was evaporated under microwave conditions (110 °C) in the presence of argon gas.  
Subsequently, the bromide precursor (in anhydrous ACN) was added to the dried [K/K222]+18F− 
complex followed by hydrolysis with sodium hydroxide and finally neutralized by the addition 





























All microorganisms, including bacteria and fungi, require iron as a trace element for their growth 
[217].  However the presence of O2 in the environment causes oxidation of ferrous (2+) to ferric 
(3+) iron which is insoluble.  Bacteria produce siderophores; which are small peptide-like 
metabolites with the ability to chelate iron thereby making it available to the organism [218].  
Moreover, a few siderophores also mediate the uptake of gallium [219, 220].  Recent 
investigations described the 68Ga radiolabeling potential of siderophores namely 
triacetylfusarinine C (TAFC) and ferrioxamine E (FOXE).  Radiolabeled 68Ga-TAFC and 68Ga-
FOXE showed rapid accumulation as well as specificity towards A. fumigatus in infected lung 
tissues.  However, it also showed moderate accumulation in sterile inflamed tissue and no affinity 
towards S. aureus infected muscle [66, 221, 222].  For radiolabeling TAFC (Scheme 34) and 
FOXE (Scheme 35), they are incubated with 68Ga in acetate buffer at room temperature and at 
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S. aureus, K. pneumoniae and E. coli -- 95% 
SPECT/CT [199] 
Ribosomal inhibitors Puromycin       68Ga S. aureus -- 65 ± 2.6 % μPET/CT [203] 
Purins and Pyrimidins FIAU 
125I 
S. aureus, E. faecalis, Proteus mirabilis, 
Pseudomonas aeruginosa etc 
14 50% 












18F E. coli, S. aureus, Enterobacteriaceae 12.4 ± 0.44 81±4% PET/CT [211] 




5.81±6.05 -- PET/CT  [221] 




4. Challenges and limitations in producing efficient infection imaging probes 
The production of radiopharmaceuticals is often expensive and requires appropriate shielding or 
particular laboratory set-up to adhere to current guidelines and rules by incorporating good 
manufacturing procedures (GMP).  A favorable imaging agent for infection imaging should be 
straightforward and rapid to manufacture, if possible at ambient temperatures.  Easy-to-radiolabel 
kit solutions may allow for inexpensive probe manufacture and generates commercialization 
opportunities.  The probe’s clinical performance may be limited by its specific activity to assure 
a sensitive discovery of any unknown infection sites as only trace amounts of the biomolecule 
forms part of the radiopharmaceutical dose.  In addition, most radiosynthesis suffer from the use 
of solvents during the radiolabeling approach, however it is desirable to eliminate all solvent 
agents as they may lead to unfavorable reactions or can manipulate the probe’s pharmacokinetics 
and biodistribution.  Regarding its chemical production, the desired imaging agent might be of 
neutral charge to avoid any unnecessary unspecific binding in vivo [223].  Moreover, the 
production of certain radioisotopes (11C, 13N, or 15O) may be a logistical obstruction due to their 
exceptionally rapid radioactive decay.  This may challenge their broad clinical application, except 
if being utilized on-site.  There is also a significant radiation burden to personnel during 
production and whilst patient administration. 
5. Conclusion 
In this review article, we discussed the potential of established and novel probes available for 
non-invasive infection imaging.  Even though substantial efforts were made to study the field of 
infection imaging tracers, only a handful of them are FDA approved and commercially available.  
Moreover, these bacterial imaging techniques are not regularly used for bacterial diagnosis in 
clinical setup.  Thus far, and despite their challenging radiosyntheses, SPECT/CT using 
radiolabeled leukocytes is considered the gold standard procedure for the diagnosis of joint 
prosthesis, endocarditis, inflammatory bowel diseases and osteomyelitis.  Since infectious 
diseases and bacterial resistance pair up to be an even greater threat to medical health and the 
world’s economy; we foresee novel imaging technologies such as PET/MRI and SPECT/MRI 
using bacteria-unique probes to be the paradigm shift required to meet the urgent need for an 
early and better diagnosis of the pathogens! 
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Abstract  
Herein, we report a mild and efficient synthesis of a NODASA-functionalized peptide, which 
was initiated with a Michael addition reaction between monomethyl fumarate and 1,4,7-
triazacyclononane. 
In radiopharmaceutics, chelators are small organic molecules that can form stable coordination 
complexes with radiometals (radioactive isotopes of various metals) and can be delivered to the 
target of interest in vivo [1]. Based on the type of radiometal-ion selectivity it can either be used 
in disease diagnosis or therapeutics [2]. In disease diagnosis; metal ions comprising of positron- 
or γ-emitting radionuclides and are used in positron emission tomography (PET) [3-5] and single-
photon emission computed tomography (SPECT),[6, 7] respectively. The α- and β-ion generating 
radioisotopes are widely employed as therapeutics in cancer treatment [8-13]. Due to its 
noninvasive, quantitative, and highly specific nature, PET imaging has become a powerful tool 
for diagnostic or therapeutic purposes. Some of the common radiometals which can be used in 




for PET, 68Ga is of choice due to its availability from enduring 68Ge/68Ga generator systems which 
offers a cost-effective alternative to the radionuclides produced by a cyclotron [5, 14]. 
Bifunctional chelators (BFC) are typically used for the development of radiolabeling; focusing 
on the in vivo target specificity and specific metal-binding capabilities. BFC contain two parts; 
one is a functional group which can readily react with the targeting molecule (e.g., peptides, 
antibodies, and nanoparticles) as well as provide a stable covalent bond to it and the other is to 
form a strong complex with the metal ion ensuring its undesired release within the recipient [15-
18].  
Significant development has been achieved in the field of oncology in the context of radiolabeled 
peptides for tissue localization and therapy [19]. In comparison to small molecules, antibodies, 
and proteins as a carrier, peptides show distinctive advantages. They are reasonably lower 
molecular weight, easier to synthesize with the development of solid-phase synthesis, compatible 
to couple with various chelators, bind many significant biological targets, display excellent tumor 
penetration, and shows rapid clearance from the recipient. Moreover, as a therapeutic, it shows 
minimal side effects compared to conventional drugs and it is non immunogenic [20, 21].  
A well-known BFC, 1,4,7-triazacyclononane-N′,N′,N′′-tri acetic acid (NOTA); is a cyclic 
polyamino carboxylic ligand which is one of the first and most efficient chelators of 64Cu and 
67/68Ga [2, 22], therefore much research and development into its derivatives has been done [2]. 
Contrary to its popularity, a large excess of NOTA is required for the complexation with a peptide 
















Figure 1 NOTA, NODASA and NODAGA 
NOTA derivatives namely NODASA and NODAGA (Figure 1) contain an additional carboxylic 
acid moiety within the macrocycle allowing the core to better saturate the hexadentate 




































Scheme 1 NODASA [24] and NODAGA [25] synthesis. 
In literature noncommercially available bis(diphenyl methyl) d,l-bromosuccinate [24] and α-
bromoglutaric acid 1-tert-butyl ester 5-benzyl [25] are typically described for the synthesis of 
NODASA and NODAGA, respectively (Scheme 1). Hence, there is a need to provide a more 
convenient synthetic approach for these functionalized chelator derivatives and their coupling to 
peptides. Herein, we report a new and facile synthetic route for the preparation of peptide-
functionalized NODASA on solid phase from readily available and cheaper starting material. 
The model peptide, YGGF from the parent peptide YGGFL, is a part of the enkephalin sequence. 
Coupling of each amino acid was carried out with HBTU/DIPEA in DMF and each step was 
monitored by the ninhydrin test. Single coupling for one hour with excess of Fmoc-protected 
amino acids were sufficient for completion of the reaction. The pure peptide product was 
observed in analytical HPLC when a small portion of the peptide was cleaved from the resin.  
Initially, the NODASA synthesis was carried out with the coupling of 4-(benzyloxy)-3-bromo-
4-oxobutanoic acid to a peptide on resin followed by addition of 1,4,7-triazacyclononane; this 
was unsuccessful due to the HBr elimination reaction (Scheme 2). Subsequently, monomethyl 
fumarate was attached to the peptide on resin, and the addition with 1,4,7-triazacyclononane was 












































Next, a Michael addition reaction between monomethyl fumarate and 1,4,7-triazacyclononane 
(Scheme 3) was carried out in solution. To our delight, the reaction proceeded to the desired 
product and proved to be regioselective for the C3 position of the alkane and was confirmed 
using 2D NMR spectroscopy. It was recrystallized in DMF with a yield of 94%. This product (1) 
was also confirmed by LC–MS (positive mode, at m/z = 260). In order to prevent self-
polymerization of 1 during the amide coupling reaction, protection of the free secondary amines 
with Fmoc-OSu was carried out. 
Compound 2 was then easily coupled to the model peptide YGGF with standard coupling 
reagents, DIC/Oxyma-Pure. The reaction was monitored by cleaving a small portion of the resin 
and further analysis via HPLC. Complete conversion into the desired diastereomeric product was 
observed at m/z = 1127. It was then subject to a standard Fmoc deprotection to yield compound 
3 which was monitored by HPLC and confirmed by LC–MS. 
The resulting free secondary amines were then successfully alkylated on resin with tert-butyl 
bromoacetate in the presence of DIPEA. Complete conversion into the product was observed 
using analytical HPLC and LC–MS (positive mode) and showed its corresponding m/z = 799 for 
compound 4. Thereafter, base hydrolysis of the ester was achieved on resin with LiOH in THF–
MeOH to furnish derivative 5 which was confirmed from analytical HPLC with 100% conversion 
of the ester. The tert-butyl groups were removed simultaneously with cleavage of the peptide 
from the resin using TFA/H2O/TIS. The final product 6 was analyzed by analytical HPLC 
followed by LC–MS characterization. Analytical HPLC showed 100% conversion into the 




An application of the conjugated functionalized peptide product was metal chelation with cold 
gallium. A period of 30 minutes at room temperature was adequate for GaCl3 in the presence of 
NaOAc for the complete complexation of NODASA–YGGF (6). The stability of gallium 
complexation was further analyzed by 500-fold excess of EDTA. However, EDTA was 
challenged for 0, 30, 60, 120, 180, and 240 min showing no significant release of gallium from 
the complex confirming the resistance towards trans chelation. 
In this study we described a facile seven-step synthesis and purification of NODASA with a 
model peptide. The combination of on- and off-resin synthetic approach was employed. We also 
successfully demonstrated the efficient conjugation of cold gallium to this NODASA–YGGF 
chelator as a potential PET imaging agent. The synthetic route provides a cheap and simple 
alternative to commercially available functionalized NODASA in the current market and could 































































1 R = H (94% yield)
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100% purity and characterized by LC–MS. HRMS (ESI+): m/z calcd. for C36H49N8O12 [M + H]: 
785.3464; found: 785.3434. 
Supporting information 
General information: 
All the chemicals were purchased from commercial sources and used without further purification. 
Mono-methyl fumarate, tert-butyl bromoacetate, N,N-diisopropylethylamine (DIPEA), lithium 
hydroxide (LiOH), tetrahydrofuran (THF), dichloromethane (DCM), dimethylformamide (DMF) 
were purchased form Sigma-Aldrich. 1,4,7 triazacyclononane was purchased from Leap 
LabChem.  Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Tyr (tBu)-OH, Fmoc-OSu and rinkamide 
MBHA were purchased from GL Biochem (Shanghai). Coupling reagents used were 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxid 
hexafluorophosphate (HATU) from Luxembourg Biotech, N,N-diisopropylethylamine (DIPEA) 
from Sigma-Aldrich , N,N′-diisopropylcarbodiimide (DIC) (Fluka, lot number BCBK8348 V) 
and oxyma (Luxembourg Biotech).  
All compounds were analyzed by RP-HPLC (Agilent 1100, USA). Runs were performed using 
a linear gradient of solvent A (0.1% TFA in H2O) and solvent B (0.1% TFA in ACN); where the 
gradient was 5% B to 95% B in 15 min at a flow rate of 1 ml/min. All the synthetic steps were 
further characterized using LCMS (Shimadzu 2020 UFLC-MS, Japan) with an YMC-Triart C18 
(5 μm, 4.6 × 150 mm) column for their respective masses.  NMR spectra (1H NMR, 13C NMR, 
HMBC and HSQC) were recorded on a Bruker AVANCE III 400 MHz spectrometer using 
deuterated methanol as the solvent. HRMS was carried out on a Bruker microTOF-QII. 
Peptide synthesis: 
The model peptide YGGF was synthesized using Fmoc chemistry in solid phase at 0.1 mmol 
scale. Amino acids were dissolved in 1.0 ml of DMF along with HATU and DIPEA followed by 
addition to the resin. The ratio of Fmoc protected amino acid to free amine was 2:1 and each 
coupling was carried out for 1hr. A ratio of 1:1:2 of amino acid: HATU: DIPEA was employed 
in the synthesis. Fmoc deprotection was performed in 4.0 ml of 20% piperdine in DMF for 5 
minutes twice. In all the steps the resin was washed with approx. 5.0 ml of DMF (2 x), DCM (2 
x) and DMF (2 x) consecutively. An aliquot of the synthesized peptide was cleaved from the 
resin and monitored by HPLC as well as LCMS.  
4-Methoxy-4-oxo-3-(1,4,7-triazonan-1-yl)butanoic acid (1): 
1,4,7-triazacyclononane (991.5 mg, 2.0 equiv.) and DIPEA (1.33 ml, 2.0 equiv.)  were dissolved 




1.0 ml DCM was added drop-wise over a period of 10-15 min. After 2 hr of agitation, the DCM 
was removed in vacuo. The product was further dissolved in 4.0 ml DMF and kept overnight at 
-20 oC for the precipitation of the (1). The DMF was decanted and the residual DMF was co-
evaporated with toluene in vacuo which gave a yield of 94%. 1HNMR (400 MHz, MeOD): δ 
3.36 (1H, t), 2.93 (2H, m), 2.74 (2H, m), 2.61-2.70 (2H, m), 2.58 (2H, m), 2.56 (3H, s), 2.36-
2.51 (5H, m), 2.24 (1H, m) ; 13C NMR (100 MHz, MeOD):  δ 179.4, 175.3, 64.4, 52.2 (2), 50.3, 
46.8 (2), 45.8 (2), 35.1. HRMS (ESI+): calcd. for C11H22N3O4 [M+H] 260.1605; found 260.1612.  
3-(4,7-Bis(((9H-fluoren-9-yl)methoxy)carbonyl)-1,4,7-triazonan-1-yl)-4-methoxy-4-
oxobutanoic acid (2): 
Compound 1 (100 mg, 1.0 equiv.) and NaHCO3 (162 mg, 5 equiv.) was dissolved in 60 ml of 
water and acetone (1:1). The mixture was cooled down to 0 oC and 286 mg (2.2 equiv.) of Fmoc-
OSu pre-dissolved in 2.0 ml acetone was added dropwise over a period of 10-15 min followed 
by overnight stirring. The reaction was then concentrated in vacuo and extracted with diethyl 
ether to remove the unreacted Fmoc-OSu. Thereafter, the resulting reaction mixture was acidified 
with 10 ml 1M HCl followed by extraction of the compound with 50 ml diethyl ether. The organic 
layer was evaporated in vacuo to give a white solid yielding 82%. LCMS (positive mode) showed 
desired m/z 704. The product was then used for the next step without further purification. 
Methyl 1-amino-2-benzyl-11-(4-hydroxybenzyl)-1,4,7,10,13-pentaoxo-15-(1,4,7-triazonan-1-
yl)-3,6,9,12-tetraazahexadecan-16-oate on resin (3): 
Compound 2 was coupled to the synthesized peptide on resin at 0.0125 mmol scale. Compound 
(2) was dissolved in 0.5 ml of DMF along with DIC and OxymaPure followed by 2 min 
activation. The entire mixture was then added to the resin containing the model peptide and the 
reaction was carried out for 16 hr. A ratio of 1:1:1: (2):DIC:OxymaPure was used in the synthesis. 
Compound (2) to free amine ratio was 2:1. In all the steps resin was washed with about 5.0 ml 
each of DMF (2 x), DCM (2 x) and DMF (2 x). The Fmoc group was removed using 4.0 ml of 
20% piperdine in DMF along with 0.5M HOBt to produce compound 3. The resin was washed 
using approx. 5.0 ml of DMF (2 x) and DCM (2 x) consecutively. An aliquot of the synthesized 
peptide was cleaved from the resin and monitored by analytical HPLC as well as LCMS. LCMS 
(positive mode) showed desired m/z 683. 
Tert-butyl 2,2'-(7-(18-amino-17-benzyl-8-(4-hydroxybenzyl)-3,6,9,12,15,18-hexaoxo-2-oxa-
7,10,13,16-tetraazaoctadecan-4-yl)-1,4,7-triazonane-1,4-diyl)diacetate on resin (4):   
Compound (3); 0.0125 mmol was swelled with 1 ml DCM for 5 min followed by filtration, to 




NMP was added and the reaction mixture left to stir for 2.5 hr [1]. The resin was washed with 
approx. 5.0 ml of DMF (2x) and DCM (2x) consecutively. An aliquot of the synthesized 
compound was cleaved from the resin and monitored by analytical HPLC. LCMS (positive mode) 
showed its desired m/z 799. 
1-amino-2-benzyl-15-(4,7-bis(2-tert-butoxy-2-oxoethyl)-1,4,7-triazonan-1-yl)-11-(4-
hydroxybenzyl)-1,4,7,10,13-pentaoxo-3,6,9,12-tetraazahexadecan-16-oic acid (5): 
The functionalized peptide on resin (4); 0.0125 mmol was swelled in 1.0 ml DCM for 5 min 
followed by filtration, and 1.0 ml of 1M LiOH (dissolved in methanol and THF in 1:1 ratio) was 
added. The reaction was carried out for a period of 30 min at room temperature.  The completion 
of the reaction was monitored by cleaving an aliquot of the compound from the resin and checked 
by LCMS as well as analytical HPLC. The resin was washed with about 5.0 ml of THF (2x), 
DMF (2x), and DCM (2x) consecutively. Compound 5 (0.0125 mmol) was deprotected and 
cleaved from the resin using a cocktail of 1.0 ml TFA:H2O:thioanisole (95:2.5:2.5) over 2 hr. 
The resin was removed by filtration and washed with 1 ml TFA. Further, TFA was evaporated 
with the aid of N2 gas bubbling through the mixture. The peptide was then precipitated in 5.0 ml 
of ice-cold diethyl ether. The precipitated peptide was centrifuged and the diethyl ether solution 
was decanted. It was then dissolved in 1.0 ml of water and freeze dried without further 
purification which gave a yield of 84%. The purity of the synthesis was checked by analytical 
RP-HPLC which showed 100% purity and characterized by LCMS. HRMS (ESI+): calcd. for 
C36H49N8O12 [M+H] 785.3464; found 785.3434. 
Conjugation of cold Ga to NODASA-Peptide:  
Cold Ga was labelled to NODASA peptide as described before by Peter A. Knetsch et. al [2]. 1.0 
mg of NODASA-peptide (6) was dissolved in 828 µl of water; 167 µl 1.9M sodium acetate and 
5 µl of 0.7M 69GaCl3. The solution was allowed to react for 15 min at room temperature. Excess 
69GaCl3 was filtered through a SPE C18 cartridge and conjugated NODASA-Peptide was eluted 
in 50% methanol. The 69Ga conjugation was further confirmed by ESI-LCMS. HRMS (ESI+): 
calcd. for C36H46GaN8O12 [M+H] 851.2486; found 851.2534. 
Transchelation assay: 
The stability of 69Ga NODAGA complexation was carried out by the EDTA challenge as 
described by previous researchers [3]. 69Ga [NODASA]-peptide was incubated with 500 fold 
excess of EDTA at room temperature. Samples were tested for transchelation at six different time 
points i.e. 0 min, 30 min, 60 min, 120 min, 180 min and 240 min respectively and monitored 
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Abstract  
LL37, a human cathelecidin antimicrobial peptide comprising 37 amino acids has emerged as 
one of the vital therapeutic peptides associated with a number of biological applications. In this 
context, we herein report a highly efficient and optimized methodology for the synthesis of LL37 
through SPPS assisted by microwave power. Standard conditions employing uronium coupling 
reagents was unsatisfactory from the 20th amino acid residue onwards. A segmentation approach 
revealed that the amide bond formation between the Val and Ile was identified as the problematic 
coupling. It was found that DIC/OxymaPure in conjunction with THF as the solvent gave best 
results during manual coupling of 20th position Ile and required double coupling as revealed by 
HPLC and MALDI-TOF MS. In order to verify the synthesis, antibacterial testing was carried 
out and the results revealed comparable values with that of literature reported.  
Keywords: LL37, SPPS, Microwave, DIC, OxymaPure, THF  
Abbreviations 
DCC: N,N′-Dicyclohexylcarbodiimide; DIC:  N,N′-Diisopropylcarbodiimide; DIPEA: N,N-
Diisopropylethylamine; DMF: N,N-Dimethylformamide; HATU: 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-
oxidhexafluorophosphate; HBTU: N-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-N-




(Benzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate; TFA: Trifluoroacetic 
acid; THF: Tetrahydrofuran  
1. Introduction  
Since the discovery of human cathelicidin protein in 1995 [1], extensive research has been 
conducted on LL37. This is a 37 amino acid residue of human cationic antimicrobial peptide 
(hCAP18) from the C-terminus and has a linear structure (Fig. 1) [1]. LL37 is widely associated 
with the innate immune system and is found in various body fluids and cells such as neutrophil 
granulocytes and human squamous epithelia [1, 2]. Besides its use as a first line of defence for 
antimicrobial activities, this peptide also plays a role in angiogenesis, cytokine production, 
histamine release, cell migration, and chemotaxis [3-8]. These biological roles enable LL37 to 
regulate immune responses, wound healing and neovascularization in injured tissues [7, 8] and 
hence can be considered as a peptide of high therapeutic value. Studies reveal contradictory 
involvement of the antimicrobial peptide in cancer [9-14]. Recently, the role of LL37 has been 
described in anti-tumor activity and tumor surveillance [9, 13, 14]. However, in contrast, different 
researchers have also reported oncogenic effects [10, 12]. As this peptide shows diversified 
biological activities, relatively large quantities are required to study its mechanism both in culture 
conditions as well as in animal models.  
 
Fig. 1 Primary structure of full length human LL37; Amino acids have been numbered 
sequentially from the N-terminus and the same has been used throughout the text 
LL37 being a “good old” peptide, synthesis of which is routinely carried out in several 
laboratories. Johansson et al. first described the use of t-butoxycarbonyl amino acid derivatives 
for the solid-phase synthesis of LL37 using double coupling of arginine, glutamine, and 
asparagine residues [15]. Since then Fmoc chemistry have been the choice approach reported by 
many research groups [5, 6, 16-22]. All of the syntheses described were vague with regards to 
reaction conditions, yields and purities. Till now LL37 has been synthesised using various 
coupling reagents including HATU/DIEA [22], PyBOP [22], DIC/HOBt [18], and DCC/HOBt 
[20]. But none of these articles describe the synthetic conditions/protocols employed. Moreover, 
to the best of our knowledge there are no reports comparing the efficiency of coupling reagents 




The established method of microwave assisted solid phase peptide synthesis has revolutionised 
this field. It has been reported to not only increase coupling efficiency but to also overcome near 
impossible coupling steps and in shorter time [23-26]. Microwave energy activates molecules 
based on its dipole rotation or ionic conduction, subsequently rapid heating of the molecule [27]. 
The heating efficiency is subjective to reactants, solvents, reaction volumes and the mode of 
mixing [28]. In microwave assisted peptide synthesis optimization of the temperature remains 
the critical factor to evade side reactions and racemization [29].  
ChemMatrix® resin performs extremely well compared to polystyrene resins in the solid-phase 
synthesis of hydrophobic, highly structured peptides such as poly-Arg peptide and β-amyloid (1-
42) [30-34]. Thus, ChemMatrix resins have been reported as the resin of choice for synthesis of 
hydrophobic and long peptides [31-33]. 
In view of the aforementioned shortcomings, in this communication we would like to describe 
for the first time the complete synthetic approach of LL37 aided by microwave assisted solid 
phase peptide synthesis using ChemMatrix resin. We also compared the coupling efficacies of 
HATU/DIPEA, HBTU/DIPEA and DIC/OxymaPure coupling systems.  
2. Materials and Methods 
2.1. Reagents 
All 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids and coupling reagents were 
purchased from GLS Biochem Systems, Inc., China and OxymaPure from (Luxembourg 
Biotechnologies Ltd., Israel). The side chain functionalities were protected with tertbutyl (Asp, 
Glu, Ser, Thr), tert-butyloxycarbonyl (Lys), NG-2,2,4,6,7-pentamethyldihydrobenzofuran-5-
sulfonyl (Arg), and trityl (Asn, Gln) groups. Rink amide-ChemMatrix resin (Loading: 0.48 
mmol/g) was purchased from PCAS BioMatrix Inc (USA). All solvents for synthesis and 
purification were of HPLC grade and purchased from Sigma-Aldrich (Germany). 
2.2. Peptide Synthesis 
Peptides were synthesized on a 0.1 mmol scale using a CEM microwave peptide synthesizer 
(USA). 
2.2.1. Deprotection:  
Fmoc deprotection was carried out with 20% piperidine/DMF (v/v) along with 0.1M HOBt under 
microwave condition at 70 °C for 2 min. Based on the previous experience/ literature, we thought 
Asp would lead to aspartimide formation in the sequence. Several acids have been used in order 




readily available, less expensive additive, HOBt (pKa = 4.60) in piperidine to reduce aspartimide 
formation [35].  
2.2.2. Coupling  
Coupling was performed using various combinations of reagents and solvents. Amino 
acid/HBTU/DIPEA in DMF 1:1:2; Amino acid/HATU/DIPEA in DMF 1:1:2 and using Amino 
acid/DIC/OxymaPure in DMF 1:1:2; Amino acid/DIC/OxymaPure in THF 1:1:1. The ratio of 
amino acid to free amine on the resin was 5:1 for all amino acids used in the peptide synthesizer. 
DMF top and bottom washes were performed between deprotection and coupling steps. The 
standard microwave settings from the manufacturer were modified according to Table 1. All 
manual coupling were performed with 1:1:1 Amino acid/DIC/OxymaPure in THF using three 
equivalents of the respective amino acids [36]. 
Table 1 Coupling conditions under different activating reagents used in this study 
















DIC/ OxymaPure in DMF 




mw 75 300 
DIC/ OxymaPure in THF No mw 25 3,600 
2.2.3. Cleavage  
Peptides were cleaved from the resin employing a mixture of 95:2.5:2.5 TFA/thioanisole/water 
for two hours. 
2.2.4. Purification of LL37  
LL37 was purified directly via an ACE C18 preparative column (150 x 21.2 mm). A two-buffer 
system was employed utilizing TFA as the ion-pairing agent. Buffer A consisted of 0.1 % 




buffer B over 30 min with a flow rate of 10 mL/min was used with UV detection at 220 nm and 
the fractions with purity >95 % were pooled, evaporated to 10 mL, frozen in liquid nitrogen and 
lyophilized. 
2.3. Peptide analysis  
Peptides were analyzed with an Agilent 1100 HPLC on a Waters XBridge C18 column (50 x 3.6 
mm) over 15 min using a gradient of 5-95 % buffer B at a flow rate of 1 mL/min and UV detected 
at 220 nm. MALDI was performed with an Autoflex III instrument (Bruker), recorded in linear 
mode using α-cyano-4-hydroxycinnamic acid (HCCA) as matrix.  
2.4. Antibacterial test 
The antimicrobial activity of LL37 was tested against two gram positive bacteria S. aureus ATCC 
25923 and E. faecalis ATCC 29212; along with two gram negative bacteria E. coli ATCC 25922 
and S. enterica ATCC 10708 using broth dilution method as described previously [37].  
3. Results and Discussion 
3.1. LL37 synthetic approaches 
Our initial attempts to synthesize the complete sequence of LL37 was with the uronium coupling 
reagents; HBTU and HATU, which gave poor results as analysed by HPLC. For these uronium 
coupling reagents double coupling was performed for all Ser, Arg, Val, Leu and Ile amino acids 
residues. A MALDI-TOF mass spectrum (Fig. 2) illustrates the non-specific products which are 
mainly found in the region from m/z 2100 to m/z 3100 along with a weak signal for the desired 
product at m/z 4493. Analysis of this region, lead us to conclude that m/z 2179 represented the 
peptide fragment with 21–37 amino acid residues incorporating two tBu protecting groups due 
to incomplete deprotection. This can be confirmed by the presence of a peak at m/z 4604 that is 
representative our desired peptide also with two tBu protecting groups. Subsequently, signals at 
m/z 2292, 2449, 2578, 2726, 2853 and 2982 represented fragments up to the 20th, 19th, 18th, 17th, 
16th and 15th amino acid residues respectively. These results implied that the coupling efficiency 
decreased from the 20th amino acid residue, i.e. the coupling of 20Ile to 21Val which persisted up 





Fig. 2 MALDI analysis of full sequence synthesis of LL37 using HATU/DIPEA as coupling 
reagent 
To investigate further, we performed the segment extension approach using HATU/DIPEA and 
the fragments identified were 33–37, 21–32, 16–20 and 11–15 (Fig. 3). In this approach, the 
amino acid sequence corresponding to the region 33-37, gave the desired peptide mass (LCMS 
ESI: m/z 587) and was successfully extended to residue 21 (Fig. S1). This efficient synthesis was 
realised with single coupling of the amino acids for 5 min at 75 °C under microwave conditions 
besides for Arg residues that needed double couplings of 25 min at 25 °C followed by 5 min at 
75 °C. Further extension of the segment (i.e. residues 16–20) gave less resolved HPLC traces and 
MALDI TOF MS revealed non-specific masses along with the desired peptide at m/z 2742 (Fig. 
S2). Even though the above mentioned coupling conditions were maintained, nonspecific masses 
at m/z 2170, 2207, 2291, 2447, 2575, 2613 as well as at 2638 were observed. These results 
correspond to inefficient coupling in this region which was increased upon further extension up 
to the 11th residue which gave rise to corresponding non-specific masses at m/z 2200–3300 (Fig. 
4). These findings proved that LL37 has difficult fragments with respect to coupling especially 





Fig. 3 Fragment-based synthetic approach of LL37 (I) fragment 33-37 (II) fragment 21-37, (III) 
fragment 16-37, (IV) fragment 11-37 and (V) fragment 1-37. Difficult coupling region/ amino 
acids as found out experimentally are shown in red. 
 
 
Fig. 4 MALDI analysis of the extended peptide fragment (11-37) 
In the next approach we synthesized the peptide with the amino acids sequence ‘‘21–37’’ in the 
synthesizer with HATU/DIPEA. We decided to use extended coupling times over the region 16–
20 and therefore needed to change the coupling reagents and conditions. A DIC-mediated 
coupling condition was chosen because it is more stable at extended durations under reaction 
conditions than standalone reagents such as HATU or HBTU [38]. Carbodiimide methods are 
usually used in combination with additives, mainly N-hydroxyamine such as HOBt, HOAt and 




HOAt) showed explosive properties [41]. Furthermore, OxymaPure showed superior 
performance over HOBt and in some cases similar results to HOAt [39, 40, 42]. Recently, we 
observed that using THF instead of DMF in combination with DIC/OxymaPure and ChemMatrix 
resin at room temperature showed an approximately double coupling efficiency than DMF during 
synthesis of difficult sequences containing Aib (α-α-disubstituted amino acid) such as Aib-
enkephalin and Aib-ACP analogues [36]. The subsequent amino acid residues; Ile, Arg, Lys and 
Phe were sequentially coupled to the 21-37 amino acid sequence manually using 
DIC/OxymaPure in THF and monitored by ninhydrin test for free amines. The Ile residue showed 
necessity for double couplings for 1 hour each; but the other amino acid residues viz. Arg, Lys 
and Phe required only single coupling reactions. This confirmed that the Ile in the 20th position 
is a problematic coupling residue as well as DIC/OxymaPure in THF is a better combination of 
coupling system for the segment Phe-Lys-Arg-Ile-Val in LL37. We synthesized the 21–37 
fragment in the automated synthesizer using DIC/OxymaPure in DMF under microwave 
conditions. The following 20Ile amino acid residue was double coupled manually using 
DIC/OxymaPure as coupling reagent in THF for one hour each at ambient temperatures. 
Subsequent extension of the sequence after this residue was completed in the synthesizer under 
microwave conditions and resulted in the desired peptide with a strong signal for m/z 4493 in 
MALDI-TOF MS of the crude product. The HPLC analysis of the crude product showed a much 
improved profile with a 52 % purity (Fig. 5a) (pure HPLC trace has been shown in Fig. 6 and 
MALDI-TOF MS in Fig. S3). We then compared if the synthesis of the entire sequence would 
benefit from these promising conditions as we found in our recent report [36] but was 
disasspointed with a lower crude yield of 40 % (Fig. 5b) that we attribute to the possible solubility 
properties associated with extended peptides. Recently, we came across an article described by 
Collins et al. [30] in which they have established a new protocol for solid-phase synthesis of 
some standard peptides. The method involves shorter coupling times with higher temperatures, 
as less as 2 min at 90 °C under microwave power. They were also successful in reducing the 
percentage of waste that would be generated by earlier methodologies. Inspired by this, we were 
interested to incorporate these conditions given in this report with minor modifications. In this 
direction, we used DIC/OxymaPure-enabled microwave assisted SPPS of LL37 using 5 min 





Fig. 5 HPLC chromatograms of synthesis of LL37 (a) modified protocol wherein only 20Ile was 
coupled manually using DIC/OxymaPure/THF (b) using DIC/OxymaPure/THF under NO 
microwave power (c) complete sequence using DIC/Oxyma/DMF under microwave 
 




3.2. Antimicrobial activities  
The HPLC purified LL37 was tested for its antimicrobial activity against S. aureus ATCC 25923, 
E. faecalis ATCC 29212, E. coli ATCC 25922 and S. enterica ATCC 10708. The corresponding 
MICs were listed in Table 2 which resembled with the previous report [37].  
Table 2 Antimicrobial activity of pure synthetic LL37 
Peptide Gram positive bacteria MIC 
(µg/mL) 










LL37 64 64 32 32 
4. Conclusion 
In short, we were successful in identifying the difficult region of LL37 peptide and described an 
efficient synthesis by microwave assisted SPPS with the necessity of manually coupling 20th Ile 
residue. The use of THF in combination with DIC/OxymaPure in the key coupling step could 
open a new vista for other difficult peptides also. We further conclude that DIC/OxymaPure 
system is better than the HBTU/DIPEA and HATU/DIPEA for this synthesis. We also verified 
the antimicrobial activity of the peptide against a panel of Gram positive and Gram negative 
bacteria which exhibited MICs comparable to previously reported values. Therefore this work 
happens to be of sufficient scientific interest from the view of researchers as well as 
pharmaceutical companies to prepare in bulk quantities. 
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Fig. S2 MALDI analysis of the extended peptide fragment (16-37) 
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Abstract 
Bacterial infections are a major concern in the human health sector due to poor diagnosis and 
development of multi drug resistant strains.  PET/CT provides a means for the noninvasive 
detection and localization of the infectious foci; however, the radiotracers available are either 
cumbersome to prepare or its exact contribution towards the imaging is not yet established.  
Human antimicrobial peptides are of interest for development as PET radiotracers as they are an 
integral component of the immune system, non-immunogenic towards the recipient and show 
selectivity towards pathogens such as bacteria.  Herein we report on the potential of LL37, a 
human cathelecidin antimicrobial peptide, as a radiotracer for bacterial imaging.  Bi-functional 
chelator 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) was utilized to 
functionalize the antimicrobial peptide, which in turn was capable of chelating gallium.  The 
synthesized natGa-CDP1 showed bacterial selectivity and low affinity towards hepatic cells, 




1. Introduction  
Bacterial infections are one of the fastest growing disease risk factors in health care despite 
significant global developments in antimicrobial chemotherapy.  Infection still remains a major 
cause of morbidity and mortality due to poor diagnosis and increasing drug resistance [1].  Due 
to the numerous mechanisms of pathogenesis, early stage diagnosis is crucial in the effective 
prevention and treatment of bacterial infections [2].  The general, bacterial identification 
procedure involves culturing and examining the microorganism from the suspected site of 
contagion, which are time consuming, laborious and require skilled personnel [3-5]. 
Alternatively, Magnetic Resonance Imaging  (MRI) [6], Computerized Tomography (CT) [7] 
and ultrasound can be used for the detection and localization of these pathogens by identifying 
the inflammatory changes in the local anatomy, water content in tissue or capillary permeability 
as a result of the infectious lesions [6, 7]. However, it is difficult for these methods to differentiate 
between sterile inflammation and bacterial infection in the absence of anatomical landmarks [2, 
8, 9].  With the disadvantages associated with anatomy-based scanning systems, Positron 
Emission Tomography Computerized Tomography (PET/CT) imaging plays a key role in the 
diagnosis of diseases [10]. One of the methods to differentiate infection from sterile inflammation 
is to use radiolabeled agents that have an affinity to the bacterial cell.  To date, various 
biomimetics, antimicrobials, leukocytes, antibodies, bacteriophages, antibiotics, sorbitol, 
maltose, maltohexaose, and siderophores have been made available for bacterial 
radiopharmaceutical imaging, but each approach has its own limitations [3-5, 10-16]. Despite of 
exponential growth in radiopharmaceutics, very few of them are commercially available and 
approved by Food and Drug Administration (FDA) for bacterial imaging; these includes 
radiolabeled leukocytes (111In-oxine-leukocyte, 99mTc-HMPAO-leukocute and 99mTc-Stannous 
Colloid), radiolabeled anti-granulocyte antibodies (99mTc-Sulesomab and 99mTc-Besilesomab), 2-
deoxy-2-(18F)fluoro-D-glucose (18F-FDG) and 67/68Ga-citrate. From these imaging techniques, 
18F-FDG-PET/CT has been considered for infection diagnosis for a long period of time, but its 
exact contribution has not yet been determined [17].  Radiolabeled leukocytes is considered to 
be the gold standard of infection imaging; however it is time consuming, labor intensive and 
requires blood handling [8].  Moreover, commercially available Gallium-67-(67Ga-) citrate shows 
low specificity along with high energy γ radiation and longer half-life (78 hr) exposing patients 
to increased radioabsorption [18]. Due aforesaid disadvantages, antimicrobial peptides can be 
consider as potential candidate for PET tracer as it tend to accumulate at the infection sites rather 
than sterile inflammation due to their preferential binding to bacteria over mammalian cells [4, 
19]. Since many of the antimicrobial peptides target bacterial cell wall proteins and lipids which 




[20]. Recently, 68Ga-DOTA-TBIA101, a small radiolabeled depsidomycin-derived bioconjugate 
has been used to detect infection sites using PET/CT scanning and is an excellent example of 
how radiolabeled peptides can be employed to distinguish infection from inflammation [12]. 
Moreover, 68Ga-NOTA-UBI fragments were also reported to show bacterial selectivity and 
specificity in vitro [21].  Furthermore, human neutrophil peptide, neutrophil elastase inhibitor 
peptide human β-defensin and human lactoferrin-derived peptide have also been successfully 
evaluated for imaging bacterial infection [22-25].  
LL37, a linear human cationic antimicrobial peptide (hCAP18) comprising of 37 amino acid 
residues from the C-terminus [26] is widely associated with the innate immune response.  LL37 
is found in squamous epithelium and neutrophil granulocytes and is constitutively released into 
the extracellular space [26, 27].  This peptide is attributed towards the neutralization of the 
bioactive molecules of the bacterial cell wall as well as growth inhibition [28, 29]. In addition to 
its antimicrobial activities as a first line defense mechanism, this peptide is also linked with 
chemotaxis, histamine release, angiogenesis, cell migration, and cytokine production [30-32]. 
These biotic roles facilitate the LL37 modulation of the immune response, neovascularization of 
injured tissues and wound healing [31, 32]. Because of its close association with the innate human 
immune response, we envisaged the suitability of LL37 as a potential radiotracer for the diagnosis 
of infection.  Furthermore and although the synthesis of this kind of large peptides can be 
considered a challenge, our group recently reported an optimized solid phase synthesis of LL37 
[33]. 
Presently, LL37 radiolabeled compounds have not been reported for differentiating infection 
from inflammation.  The bifunctional chelator, 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic 
acid (NODAGA), has gained popularity for radiolabeling of peptides because of its in vivo 
stability [34].  In this proof of concept study, we developed NODAGA-functionalized LL37 and 
conjugated it with natGa.  We also present natGa-CDP1 uptake in different bacteria and a 
hepatocellular carcinoma (HepG2) cell line.  Additionally, the radiosynthesis of CDP1 with the 
PET radioisotope gallium-68, including its identification by radio-HPLC/UV analysis is 
reported. 
2. Methods and Materials 
2.1. Materials 
NODAGA(tBu)3 was purchased from CheMatech (Dijon, France).  All Fmoc protected amino 
acids, coupling reagents and the resin Rink Amide-MBHA were purchased from GLS Biochem 




2.2. Peptide synthesis  
LL37 was synthesized as described in our previous publication using SPPS and Fmoc chemistry 
on 0.1 mmol scale [33]. The synthesis was confirmed by cleaving an aliquoted amount of resin 
followed by matrix-assisted laser-desorption ionization (MALDI) (Autoflex III smartbeam; 
Bruker Daltonics, Bremen, Germany) analysis. MALDI (positive mode) showed the product with 
m/z 4493.  
2.1.1. Coupling of NODAGA(tBu)3 to the peptide and cleavage  
NODAGA(tBu)3 was coupled to LL37 on resin at 0.1 mmol scale using N,N′-
diisopropylcarbodiimide (DIC)/OxymaPure to synthesize CDP1.  The mixture of 
NODAGA(tBu)3, DIC and OxymaPure was dissolved in tetrahydrofuran (THF) (0.1 ml) and 
allowed to react for 16 hr at room temperature.  The ratio of NODAGA (tBu)3/DIC/OxymaPure 
was 1:1:1 whereas NODAGA (tBu)3 to free amine ratio was 1.2:1.  Excess reagents were 
removed by washing the resin with 5 ml of THF (2 x) and DCM (2 x), consecutively.  The tBu 
protected NODAGA attached to side chain protected LL37 peptide was finally cleaved from the 
resin using a cocktail of 1.0 ml TFA:H2O:thioanisole (95:2.5:2.5) over a 2 hr period.  During 
cleavage of the peptide from the resin, all protective groups were also removed.  The resin was 
removed by filtration and washed with TFA (1.0 ml), which was then evaporated upon bubbling 
of N2 gas through the mixture.  The peptide was precipitated in 5.0 ml of ice-cold diethyl ether 
and centrifuged. The precipitate was then dissolved in 1.0 ml of water and further purified using 
prep-HPLC.  The final product was characterized by MALDI-MS, revealing an m/z 4849 for 
CDP1 in positive mode. 
2.1.2. CDP1 purification  
CDP1 was purified on an ACE C18 preparative column (150 x 21.2 mm) by preparative HPLC 
(Shimadzu, Kyoto, Japan).  A two-buffer system consisting of 0.1 % formic acid (FA)/H2O (v/v) 
and 0.1 % FA/acetonitrile (v/v) were employed. A gradient of 15–80 % of 0.1 % FA/acetonitrile 
(v/v) over 30 min with a flow rate of 10 ml/min was used and the fractions were characterized 
by LC-MS (Shimadzu, Kyoto, Japan).  Fractions which showed the desired mass were pooled 
and lyophilized and store for use in further experiments.  The retention time of the compound on 
prep-HPLC was 21.6 min.  
2.3. Non-radioactive natGa-labeling of CDP1 
Non-radioactive natural Gallium(III)chloride (natGa; i.e. Gallium has two natural stable isotopes, 
namely, 69Ga (60 %) and 71Ga (40 %)) was utilized to label the CDP1 as previously described 
[35].  Therefore, 1.0 mg of CDP1 was dissolved in 828 μl of water; 167 μl 1.9 M sodium acetate 




Quantitative labeling of natGa-CDP1 was confirmed by Q-TOF LC-MS (Bruker Daltonics, 
Bremen, Germany).  
2.4. LC-MS method for quantification of natGa-CDP1 
Quantification of natGa-CDP1 was carried out on a Maxis LC-MS (Bruker Daltonics, Bremen, 
Germany) coupled with an Agilent 1100 HPLC equipped with a YMC Triart C18 column (3.0 
mm x 150 mm).  Mobile phase A was water with 0.1% formic acid (FA) and mobile phase B was 
acetonitrile with 0.1% FA, the HPLC parameters were as follows: the flow rate was 0.3 mL/min 
with a linear gradient from 5% to 95% phase B over a period of 15 min, hold 2 min at 95% phase 
B and finally re-equilibration at 5% phase B for 2 min.  The mass spectrometer was used in 
positive ion mode, with a nebulizer pressure of 1.5 bar, dry gas flow rate of 8.0 L/min, drying 
temperature of 180 °C and capillary voltage of 5500V.  The retention time of natGa-CDP1 was 
10.1 min. 
2.5. Uptake of natGa-CDP1 by S.aureus, E.coli and M. smegmatis  
To determine the uptake of natGa-CDP1 by S.aureus, E.coli and M.smegmatis, 105 bacterial cells 
from each bacterial strain were incubated with natGa-CDP1 at a final concentration of 20 µg/ml.  
Uptake rates were determined at 4 and 37 oC temperatures. Samples were collected at 0, 1, 2 and 
3 hr time points post inoculation. Samples were then centrifuged at 15000 rpm for 10 min at 4 
°C (Hermle, GmBH, Germany, Rotor 221, 23) and the supernatants were collected.  The 
supernatants were treated with equal amounts of ice cold acetonitrile and vortexed for 30 sec 
followed by a 2 hr cooling step at -20 °C.  The samples were centrifuged at 15000 rpm for 10 
min at 4 °C and passed through C18 SPE cartridge (Waters, Milford, MA, USA) preconditioned 
with 100 % acetonitrile.  All the samples were diluted in the same manner and the recovered 
amounts of the Ga-CDP1 in the media was determined by the optimized LC-MS method 
described in the previous section.  
2.6. Uptake of natGa-CDP1 by hepatocellular carcinoma (HepG2) cells  
HepG2 cells were obtained from Highveld Biologicals (Johannesburg, South Africa). Cells were 
cultured in Eagle’s minimum essential media (Lonza Biowhittaker, Basel, Switzerland) 
supplemented with 10% foetal calf serum, 1% L-Glutamine and 1% pen/strep-fungizone (Sigma-
Aldrich, St Louis, USA); in a humidified incubator at 37 ºC with 5% CO2.  Cells were then seeded 
in 6-well culture plates (200,000 cells/well) and allowed to adhere overnight prior to treatment.  
The peptide was administered once the cells had reached approximately 80% confluency.  Cells 
were treated with 20 µg/ml of the compound in triplicate at 4 °C and 37 ºC temperatures.  The 
cell culture supernatant was aspirated at 0, 1, 2 and 3 hr time points and the samples collected for 




Germany; Rotor 221, 23) for 10 min at 4 °C and the supernatants were collected.  The collected 
supernatants were treated with an equal amount of ice cold acetonitrile and vortexed followed by 
a 2 hr cooling step at -20 °C.  Finally, the samples were centrifuged at 15,000 rpm for 10 min at 
4 °C and passed through C18 SPE cartridge preconditioned with 100 % acetonitrile.  All samples 
were diluted in the same manner and the recovered amount of the natGa-CDP1 in the media was 
determined by LC-MS. 
2.7. 68Ge/68Ga-Generator elution and 68Ga-radiolabeling  
Gallium-68 (68Ga: 89 %; EC β+ max. 1.9 MeV, half-life: 68 min) was yielded from an 1850 MBq-
loaded, tin-dioxide-based 68Ge/68Ga generator (iThemba LABS, Somerset West, South Africa).  
The eluate fractionation and the radiolabeling was conducted by adapting a previously described 
method [21].  Briefly, the 68Ge/68Ga-generator provided radioactivity concentrated in 2 ml 0.6 M 
HCL which was buffered with 2.5 M sodium acetate trihydrate to yield a selected pH range of 
3.5-4.0 where gallium is in its reactive state, the [Ga(OH2)6)3+] ion, which allows rapid 
complexation to the chelator molecule.  CDP1 was dissolved in Millipore water to achieve a 
peptide stock concentration of 1 μg/μl necessary to develop the radiolabeling protocol. A 0.5 ml 
aliquot of buffered 68Ga3+ (122 - 150 MBq) was mixed with 10-20 nmol CDP1, NODAGA 
(positive control) and LL37 (negative control) and was incubated at room temperature for at least 
5 min followed by HPLC/UV analyses. 68Ga-labeled c(RGDyK)-isothiocyanabenzyl-1,4,7-
triazaclononane-1,4,7-triatetic acid (NOTA-RGD), an imaging agent for integrin receptor 
expression in cancer, was radiolabeled as previously described and employed as a radiolabeling 
performance reference (to reflect any variability in the generator eluate quality) [36].  
2.8. Identification of the 68Ga-CDP1 using UV/radio-HPLC analysis  
For determination of the % RCP a reverse-phase HPLC column (Zorbax SB C18, 4.6 × 250 mm 
× 5 µm; Agilent Technologies, CA, USA) using a 5-95% A-B gradient (over 15 min) at a flow 
rate of 1 mL/min, was employed. Solvent A consisted of 0.1 % aqueous trifluoroacetic acid 
(TFA); solvent B utilized 0.1 % TFA dissolved in acetonitrile. The HPLC apparatus (Agilent 
1200 series HPLC instrument, Agilent Technologies Inc., Wilmington DE, USA) contained a 
radioactive detector (Gina Star, Raytest, Straubenhardt, Germany) following radioactivity 
(counts per second) combined with a diode array detector following UV absorbance at 214, 220 
and 240 nm. For determination of the radiolabeling efficiency (%LE) HPLC analysis was 
supported by control measures using radio-ITLC employing a silica-gel based solid phase and 
0.1 M sodium citrate as mobile phase (free 68Ga [Rf=0.8] and 68Ga-CDP1 [Rf=0.2]). Both 
methods were utilized to detect 68Ga-CDP1 and differentiate it from uncomplexed 68Ga, potential 




fractionated LL37-NODAGA where possible. The retention times for 68Ga, NODAGA, CDP1 
and NOTA were established and used for identification. 
2.9. Biostatistics  
If not indicated otherwise, results are expressed as mean ± standard deviation of mean (SD). 
Paired and unpaired Student-t tests were performed to indicate significance to compare different 
parameters and P values ≤ 0.05 were considered significant. 
3. Results and Discussion 
3.1. Synthesis of CDP1 and natGa-conjugation  
The peptide LL37 was successfully synthesized with the coupling reagents DIC/OxymaPure in 
DMF using automatic microwave synthesis except for the coupling of 20th Ile residue in solid 
phase in which manual coupling in THF was necessary. The resultant product gave the desired 
m/z of 4493 using MALDI-TOF MS.  The peptide functionalization with NODAGA was 
achieved in solid-phase using DIC/OxymaPure in THF at room temperature for 16 hrs to give 
the desired m/z of 4849 (Scheme 1). natGa was complexed to the CDP1 using sub-millimolar 
concentrations of natGa3+ as previously reported [35].  The complexation was confirmed by 


































Scheme 1. Synthesis of CDP1 
3.2. Bacterial and Hepatocellular uptake of the natGa-CDP1  
The results of the bacterial and hepatocellular uptake of the natGa-CDP1 are presented in Figures 
1A and 1B. The uptake was studied at two temperatures (4 oC and 37 oC).  At lower temperature 
(4 oC), the bacterial cell growth will be slower.  Slightly lower uptake of the conjugate natGa-
CDP1 at 4 oC was observed compared to 37 oC.  The conjugated peptide was also examined for 
its antimicrobial activity, which showed no bacteriostatic effects to S. aureus, E. coli and M. 
smegmatis at the concentrations applied in this study. 
At both temperatures, the amount of natGa-CDP1 determined in the supernatant of the HepG2 




result reveals that there was <1% uptake of the compound by the HepG2 cells regardless of the 
incubation temperature.  In the same time, bacterial cells consumed 50-120 times more Ga-CDP1 
as compared to HepG2 cells. This experiment reveals that the compound has negligible affinity 
towards the mammalian cells. 
 
Figure 1. Comparison of natGa-CDP1 uptake by cellular (HepG2) and bacterial cells at (A) 4 oC 
and (B) 37 oC. Mean results ± SD (n=3) is presented. *) Paired 1-tailed Student-t test on the 
comparison of consecutive incubation times returned P<0.05. ¥) Paired 1-tailed Student-t test 
comparing cells incubated at 4oC to 37oC returned P<0.05. 
3.2.1. Uptake of natGa-CDP1 by S.aureus  
The natGa-CDP1 uptake by the gram positive candidate, S.aureus, was determined immediately 
and compared after 1, 2 and 3 incubation periods at 4 °C and 37 °C.  At 4 °C the concentration of 




natGa-CDP1 was taken up by S. aureus.  Likewise, at 37 °C the concentration of the conjugated 
peptide taken up was 20% after 3 hr. All of the data were found to be within the allowed error 
limit of analytical method development guideline [37]. This bacterial uptake result suggests 
selectivity of the peptide towards gram positive S. aureus over HepG2 cells.  
3.1.2. Uptake of natGa-CDP1 by E. coli  
The uptake of natGa-CDP1 by E. coli was also determined at the time points described in the 
previous section. The results revealed that 22% and 21% of the compound was accumulating in 
E. coli cells at 4 °C and 37 °C after 3 hrs of incubation, respectively.  This positive uptake of 
natGa-CDP1 by E. coli cells opens the opportunity to explore the efficacy of this peptide to be 
used as a PET radiotracer for infection diagnosis against gram-negative bacteria.  
3.2.3. Uptake of natGa-CDP1 by M. smegmatis  
Acid fast M. smegmatis represents mycobacteria for this uptake study because it is non-
pathogenic and it has fast replicating time when compared to other members of this family.  This 
bacteria shares a similar cell wall structure and more than 2000 homologous genes with M. 
tuberculosis [38].  Normalization of the data at the 0 hr with the 3 hr incubation time points for 
the compound showed 18% and 28% uptake by this bacterial cell at 4 °C and 37 °C, respectively.  
These results indicate potential affinity of natGa-CDP1 towards Mycobacterium sp. and should be 
further explored.  
The in vitro results may allow translating the outcome for potential in vivo applications. The high 
degree of differentiation between bacterial and mammalian cell uptake may be reflected by the 
high targeting ability of natGa-CDP1, which may lead to potential detection of bacteria.  The 
results show no significant difference in the uptake behavior between the bacterial strains 
evaluated, suggesting no bacterial selectivity of natGa-CDP1 towards bacterial identification. 
3.3. 68Ge/68Ga-Generator elution and 68Ga-radiolabeling  
In 68Ge/68Ga-Generator elution, the fractionation method yielded 78 ± 5 % and 91± 4 % (360- 
560 MBq) of the total elutable 68Ga-activity in 1 and 2 ml, respectively.  NODAGA and CDP1 
were labeled successfully within 5 min at room temperature with a percentage radiochemical 
purity (% RCP) of > 88 % adapting conditions from a former study radiolabeling NOTA-UBI. 
[21] 68Ga-CDP1 was stable in its formulation throughout the 60 min period tested.  To the best 
of our knowledge, this is the first (documented approach presenting) report showing the 
successful 68Ga-radiolabeling of this bioconjugate.  The results suggest an optimization of the 




not considered within the scope of this study.  As a reference peptide NOTA-RGD was 
radiolabeled successfully achieving >82 % radiolabeling efficiency (%LE).   
3.4 Identification 68Ga-CDP1  
The chromatographic method was capable of confirming successful radiolabeling (peak 
integration) of 68Ga-CDP1 (Figure 2).  The retention times of 11.5-12 min allowed significant 
differentiation from the unbound buffered 68Ga (2.3-3.5 min).  Separately radiolabeled 68Ga-
NODAGA just used as a control was detected at retention times of 4- 4.2 min, but no notable 
68Ga-activity peak was detected during HPLC analyses of any 68Ga-CDP1 samples at that 
retention time.  
 
Figure 2. Representative radio-HPLC chromatogram showing successful differentiation of free 
68Ga (#1: 2.3-3.5 min retention) and 68Ga-CDP1 (#2: 11.5-12 min retention). Quantification 
following radio-peak integration resulted in a 91% RCP for 68Ga-CDP1.  
The reference radiolabeled peptide (68Ga-NOTA-RGD) confirmed 68Ga-labeling performance of 




which was expected due to the increased polar character of NOTA-RGD compared to CDP1.  
The % LE for NOTA-RGD was well within the expected range, which indicates that the generator 
eluate quality was not a compromising parameter to yield the highest possible radiolabeling 
efficiency and yield.  All retention times corresponded well with their respective UV peak 
maxima (wavelength ranged 212-260 nm).  Following incubation with 68Ga, unfunctionalized 
LL-37 was detected at 10.50 min (UV 214 and 220 nm) showing no radioactivity peak at this 
retention time using radio-HPLC.  
It should be noted that the use of NODAGA allows for radiolabeling at room temperature, which 
can be beneficial for radiolabeling heat-vulnerable peptides [39].  Based on this identification of 
radiolabeled 68Ga-CDP1, further refinements can be carried out to optimize the radiolabeling 
technique aiming for both, quantitative complexation and thermodynamic stability of 68Ga to 
CDP1. 
4. Conclusion  
In this proof of concept study, we reported the functionalization of LL37 with NODAGA and its 
usability as a PET radiotracer for potential infection imaging using gallium.  natGa-CDP1 showed 
significant affinity towards bacterial cells; it also has a low association with HepG2 cells, 
affording specific bacterial uptake. In conclusion, this complex can potentially be used as a 
candidate for preclinical studies in infection imaging. 
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Supplementary figure 1. Product ion spectra of natGa-NODAGA-LL37 showing 703,41 m/z, 




Supplementary figure 2. Typical chromatogram for natGa-NODAGA-LL37, showing its 
















Supplementary figure 3. Calibration curve, created using QuantAnalysis (Bruker Daltonics, 























The first part of the thesis reviews the synthetic approaches for existing radiotracers for the 
purpose of bacterial imaging.  Essentially, these radiotracers have been divided into two 
categories in the review 1) commercially available tracers and 2) novel imaging probes for 
bacterial infections.  Commercially available tracers that are FDA approved are mostly based on 
leukocytes.  This category can be further classified as i) radiolabeled leukocytes (111In-oxine-
leukocyte, 99mTc-HMPAO-leukocute and 99mTc-Stannous Colloid), ii) radiolabeled anti-
granulocyte antibodies (99mTc-Besilesomab and 99mTc-Sulesomab) and iii) unspecific 
biomolecules such as 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) and 67/68Ga-citrate.  These 
available radiotracers cover a vast range of modules that include (but not limited to) spatial 
localization of infection for gram-positive and gram negative bacteria, infection in soft tissues, 
endocarditis, neurological infections, fever of unknown origin, diabetic foot, inflammatory bowel 
disease, prosthetic graft infection, abdominal sepsis, osteomyelitis, pyrexia of unknown origin, 
appendicitis and acute myocarditis.  On the other hand, the novel imaging radiotracers for the 
bacterial imaging are categorized based on their source of origin.  Potential origin of these tracers 
are antimicrobial peptides, antibiotics, vitamins, aptamers, puromycin, glycopyranose derivatives 
and siderophores.  Majority of these compounds are labelled with radioisotopes such as 68Ga, 
99mTc, 125I, 18F, 111In and 11C.  The most commonly employed reducing agent for successful 
conjugation/coupling of the radioisotope to the tracer molecule is found to be SnCl2.  Moreover, 
various modalities used for the detection of the radio signals includes scintigraphy, SPECT and 
PET.  These novel tracers were successfully evaluated for imaging infections caused by 
microorganisms such as Staphylococcus aureus, Escherichia coli, Candida albicans, Aspergillus 
fumigatus, Klebsiella pneumonia and Mycobacterium tuberculosis. However, despite extensive 
studies in the area of radiopharmaceutics development, only a handful of them cross the barrier 
of clinical trial to reach commercial levels. In recent years, numerous radiotracers for bacterial 
imaging have been developed; these molecules demonstrated promise in small animals; but never 
reached the clinical stage. From the angle of nuclear imaging, PET/CT and PET/MRI are the 
most useful methods as it can be applied to whole body imaging with great sensitivity and 
promising spatial resolution. This extended the horizon for the development of more promising 
radiopharmaceutics for bacterial imaging. To be a successful PET tracer, its radio synthesis is 
expected to be simple, preferably a single step radiolabelling with radion active atoms such as 




potential candidates of radiopharmaceutics, which may be used successfully for bacterial imaging 
in near future. 
In radiopharmaceutics bifunctional chelators (BFC) are utilized for the development of 
radiotracers. These molecules act as bridge between the tracer moiety and the radioisotope.  The 
functional group present in the BFCs are used to covalently couple it to the tracking molecules 
such as peptides, antibodies and nucleotides. Moreover, the pharmacokinetic properties such as 
bio distribution and renal excretion are greatly affected by the characteristics of radiometal-
chelator complex. This makes the selection procedure of the BFCs crucial for the success of a 
radiotracer.  The next part of the thesis focused on the synthetic approach of BFC, where a facile 
method for on and off resin synthesis of a 1,4,7-triazacyclononane-N′,N′,N′′-tri acetic acid 
(NOTA) derivative 1,4,7-triazacyclononane-1-succinic acid-4,7-diacetic acid (NODASA) 
functionalized peptide (YGGF) was established. NODASA can successfully be used to chelate 
radioisotopes 64Cu and 68Ga, which make it as a potential BFC in the field of PET tracer 
development. A short sequence of peptide YGGF was synthesized on rinkamide MBHA resin 
with coupling reagent HBTU/DIPEA; this was used as a model peptide for the entire synthesis. 
A failed attempt was encountered with the NODASA synthesis when coupling 4-(benzyloxy)-3-
bromo-4-oxobutanoic acid to the model peptide on resin followed by the addition of 1,4,7-
triazacyclononane; that resulted in a HBr elimination reaction. Furthermore, monomethyl 
fumarate was coupled with the peptide followed by addition of 1,4,7-triazacyclononane, which 
resulted in another unsuccessful attempt. However, a successful seven-step synthesis was 
initiated with a Michael addition reaction between monomethyl fumarate and 1,4,7-
triazacyclononane (94% yield); and terminated with a product of NODASA-YGGF giving an 
isolated yield of 84%.  NODASA-YGGF was also efficiently conjugated with cold gallium. 
Additionally, a 500 fold excess of EDTA was used to evaluate the stability of the gallium 
complexation, ensuring no significant trans chelation even after 240 min. These results confirm 
the potential of a synthetic route for constructing PET imaging agents.  This synthetic approach 
can be attempted on other peptides of interest and provide a cheap alternative to the commercially 
available NODASA.  
LL37 is a cationic antimicrobial peptide originating from humans.  This peptide comprises of 37 
amino acids (1LLGDFFRKS10KEKIGKEFKR20IVQRIKDFLR30NLVPRTE37S) and has 
potential toward therapeutic applications because of its close association with the human immune 
system. Moreover, this peptide is also involved in different biological processes such as cytokine 
production, chemotaxis, release of histamine, angiogenesis and cell migration. In the third section 




reagents along with a combination of solvents were evaluated for optimisation.  The synthesis of 
LL37 was not satisfactory when it was attempted with HBTU and HATU in DMF, despite the 
use of double couplings in certain amino acid residues such as Ser, Arg, Val, Leu and Ile under 
microwave conditions.  However, MALDI results for the above synthesis represented a decrease 
trend of coupling efficiencies after the 20th amino acid, which represents the 20Ile to 21Val 
coupling.  Further, to identify the difficult amino acid coupling combinations of the sequence, a 
segment extension approach was performed using HATU/DIPEA.  This again confirmed that the 
16-20 amino acid residues were critical coupling combinations.  After the difficulties with certain 
segments were determined, the region 21–37 were synthesized using HATU/DIPEA in the 
synthesizer under microwave conditions.  However, the subsequent amino acid residues (16-20) 
were coupled manually to the progressing sequence at ambient temperature using 
DIC/OxymaPure in THF.  This coupling reagent combination is stable for longer times in 
comparison with HATU and HBTU.  This synthesis gave promising results proving that 20Ile to 
21Val coupling difficulties can be overcome by the DIC/OxymaPure in THF.  Finally, 
DIC/OxymaPure in THF was utilized for synthesis of the segment 20-37 of the peptide under 
microwave conditions followed by manual coupling of the 20Ile at ambient temperature.  Rest of 
the sequence was again extended in the synthesizer using the same combination of coupling 
reagents giving 52% of the crude product.  The synthesized peptide was also verified for 
antimicrobial activity against Gram positive and Gram negative bacteria which was comparable 
to previously reported MICs.  
The naturally occurring antimicrobial peptides are the rational biomarkers for the development 
of the possible vector for PET tracers; due to the fact that they show low toxicity, high target 
specificity and non-immunogenicity to the recipient. Moreover, these biomolecules are easy to 
scale up in the laboratory environment, which may also affect the cost of production. Based on 
these facts, in the last section of the thesis, LL37 was successfully coupled with the bifunctional 
chelator NODAGA using DIC/OxymaPure in THF at room temperature for 16 hr.  This 
NODAGA-LL37 was successfully complexed with natGa. Moreover, radiolabelling of 
NODAGA-LL37 with 68Ga was obtained within 5 min at room temperature. Furthermore, natGa-
NODAGA-LL37 was evaluated against gram positive S. aureus, gram negative E. coli and acid 
fast bacteria M. smegmatis along with mammalian hepatic originated HepG2 cells in vitro. The 
results showed bacterial specificity of the compound rather than affinity towards mammalian 
cells making it a potential radiotracer for infection imaging.  However, this was a proof of concept 
study that needs to be further evaluated in animal models. 
